

Stock Code: 4123

Center Laboratories, Inc. and Subsidiaries
Consolidated Financial Statements and Independent Auditors' Review Report
For the Six Months Ended June 30, 2025 and 2024

Address: 7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.)

Tel: (02)2655-8680

Independent Auditors' Review Report

The Board of Directors and Shareholders of Center Laboratories, Inc.

Introduction

We have reviewed the accompanying consolidated balance sheets of Center Laboratories, Inc. and its subsidiaries as of June 30, 2025 and 2024, the related consolidated statements of comprehensive income for the three months ended June 30, 2025 and 2024, and for the six months ended June 30, 2025 and 2024, the consolidated statements of changes in equity and cash flows for the six months then ended, and the related notes to the consolidated financial statements (including a summary of significant accounting policies). Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34 "Interim Financial Reporting" endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China. Our responsibility is to express a conclusion on the consolidated financial statements based on our reviews.

Scope of Review

Except as explained in the following paragraph, we conducted our reviews in accordance with the Standards on Review Engagements of the Republic of China 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Basis for Qualified Conclusion

The financial statements of non-significant subsidiaries were not reviewed by independent auditors. Those statements reflect total assets of NT\$4,442,281 thousand and NT\$5,932,100 thousand, constituting 18.8% and 21.9% of the consolidated total assets, and total liabilities of NT\$7,003 thousand and NT\$588,575 thousand, constituting 0.1% and 7.1% of the consolidated total liabilities as of June 30, 2025 and 2024, respectively; and total comprehensive (loss) income of NT\$(445,245) thousand and NT\$(223,683) thousand, constituting 151.4% and 39.4% of the consolidated total comprehensive (loss) income for the six months ended June 30, 2025 and 2024, respectively.

The valuation of investments accounted for using the equity method, which includes investments in associates, is based on the financial statements of those companies for the same period that were not reviewed by independent auditors. The investments accounted for using the equity method amounted to NT\$3,615,974 thousand and NT\$4,064,276 thousand, constituting 15.3% and 15.0% of the consolidated total assets as of June 30, 2025 and 2024, respectively. The share of profit (loss) from associates accounted for using the equity method amounted to NT\$(10,092) thousand, NT\$38,802 thousand, NT\$9,494 thousand, and NT\$25,893 thousand for the three months ended June 30, 2025 and 2024, and for the six months ended June 30, 2025 and 2024, respectively.

Qualified Conclusion

Based on our reviews and the review reports of other independent auditors, except for the adjustments to the consolidated financial statements, if any, as might have been determined to be necessary had the financial statements of non-significant consolidated subsidiaries and certain investments accounted for using the equity method been reviewed by independent auditors, that we might have become aware of had it not been for the situation described above, nothing has come to our attention that causes us to believe that the accompanying consolidated financial statements do not present fairly, in all material respects, the consolidated financial position of Center Laboratories, Inc. and its subsidiaries as of June 30, 2025 and 2024, and of its consolidated financial performance for the three months ended June 30, 2025 and 2024, and for the six months ended June 30, 2025 and 2024 and its consolidated cash flows for the six months ended June 30, 2025 and 2024, in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and International Accounting Standard 34, "Interim Financial Reporting," that came into effect as endorsed by the Financial Supervisory Commission.

Other Matter - Making reference to the reviews of other independent auditors

For the aforesaid subsidiaries disclosed in the consolidated financial statements as of June 30, 2025, the consolidated financial statements of Bioflag International Corporation and its subsidiaries were not reviewed by the Group's CPA. Those financial statements were reviewed by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts for the aforesaid subsidiaries, are based solely on the report of other auditor. Total assets of the consolidated financial statements amounted to NT\$1,954,420 thousand, constituting 8.3% of the consolidated total assets as of June 30, 2025; concurrently, total operating revenue amounted to NT\$148,346 thousand and NT\$282,081 thousand, constituting 39.2% and 37.2% of the consolidated total operating revenue for the three months ended June 30, 2025, and for the six months ended June 30, 2025, respectively.

Among the invested companies accounted for using the equity method disclosed in the consolidated financial statements, the financial statements of BioGend Therapeutics Co., Ltd., Lumosa Therapeutics Co., Ltd., Anya Biopharm Inc., and Medeon Biodesign, Inc., were not reviewed by our CPA. Those financial statements were reviewed by another auditor whose reports have been thereon furnished to us, and our opinions expressed herein, insofar as it relates to the amounts included in the financial statements, are based solely on the report of other auditor. These investments accounted for using the equity method amounted to NT\$1,247,526 thousand and NT\$1,343,371 thousand, constituting 5.3% and 5.0% of the total assets as of June 30, 2025 and 2024, respectively. The share of profit (loss) from associates accounted for using the equity method amounted to NT\$(128,736) thousand, NT\$(52,572) thousand, NT\$(230,243) thousand and NT\$(155,401) thousand, constituting 14.1%, 41.2%, 106.3% and 21.9% of the income before income tax for the three months ended June 30, 2025 and 2024, and for the six months ended June 30, 2025 and 2024, respectively.

The engagement partners on the reviews resulting in this independent auditors' review report are Cheng, Chung-Hao and Chi, Chia-Yu.

Full-Fill & Co., CPAs

Taipei, Taiwan

Republic of China

August 12, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to review such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' review report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' review report and consolidated financial statements shall prevail.

Center Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheets
As of June 30, 2025, December 31, 2024, and June 30, 2024

| | | | In Thousands of New Taiwan Dollars | | | | | |
|--------------|---|---------|------------------------------------|------------|----------------------|------------|----------------------|------------|
| Account Code | Assets | Notes | June 30, 2025 | | December 31, 2024 | | June 30, 2024 | |
| | | | Amount | % | Amount | % | Amount | % |
| 11XX | Current assets | | | | | | | |
| 1100 | Cash and cash equivalents | 6(1) | \$ 337,619 | 2 | \$ 1,442,273 | 6 | \$ 1,976,701 | 7 |
| 1110 | Financial assets at fair value through profit or loss | 6(2), 8 | 304,961 | 1 | 257,998 | 1 | 302,637 | 1 |
| 1136 | Financial assets at amortized cost | 6(3) | 176,431 | 1 | 350,009 | 1 | 384,857 | 2 |
| 1150 | Notes receivable, net | | 20,081 | — | 24,106 | — | 36,002 | — |
| 1170 | Accounts receivable, net | 6(4) | 201,484 | 1 | 178,579 | 1 | 186,434 | 1 |
| 1200 | Other receivables | 7 | 30,800 | — | 11,367 | — | 870,394 | 3 |
| 130X | Inventories | 6(5) | 315,754 | 1 | 309,703 | 1 | 272,677 | 1 |
| 1476 | Other financial assets | 8 | 1,182,368 | 5 | 1,183,483 | 5 | 1,226,379 | 5 |
| 1470 | Other current assets | | 22,779 | — | 23,989 | — | 40,328 | — |
| 11XX | Total current assets | | <u>2,592,277</u> | <u>11</u> | <u>3,781,507</u> | <u>15</u> | <u>5,296,409</u> | <u>20</u> |
| 15XX | Non-current assets | | | | | | | |
| 1510 | Financial assets at fair value through profit or loss | 6(2), 8 | 12,884,125 | 55 | 13,048,724 | 51 | 12,967,878 | 48 |
| 1550 | Investments accounted for using the equity method | 6(6), 8 | 5,236,463 | 22 | 5,761,850 | 23 | 5,868,705 | 22 |
| 1600 | Property, plant and equipment | 6(7), 8 | 1,463,497 | 6 | 1,415,920 | 5 | 1,341,204 | 5 |
| 1755 | Right-of-use assets | 6(8) | 13,162 | — | 17,080 | — | 21,680 | — |
| 1760 | Investment property, net | 6(9), 8 | 660,229 | 3 | 662,247 | 3 | 664,276 | 2 |
| 1780 | Intangible assets | 6(10) | 757,050 | 3 | 780,347 | 3 | 803,846 | 3 |
| 1840 | Deferred tax assets | 6(22) | 31,030 | — | 32,505 | — | 13,411 | — |
| 1920 | Refundable deposits | | 8,545 | — | 9,127 | — | 8,904 | — |
| 1915 | Prepayments | | 11,996 | — | 13,959 | — | 54,834 | — |
| 1975 | Net defined benefit asset | | 15,402 | — | 13,909 | — | 8,422 | — |
| 15XX | Total non-current assets | | <u>21,081,499</u> | <u>89</u> | <u>21,755,668</u> | <u>85</u> | <u>21,753,160</u> | <u>80</u> |
| 1XXX | Total assets | | <u>\$ 23,673,776</u> | <u>100</u> | <u>\$ 25,537,175</u> | <u>100</u> | <u>\$ 27,049,569</u> | <u>100</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Balance Sheets
As of June 30, 2025, December 31, 2024, and June 30, 2024

| | | | In Thousands of New Taiwan Dollars | | | | | |
|--------------|---|-----------|------------------------------------|------------|----------------------|------------|----------------------|------------|
| Account Code | Liabilities and Equity | Notes | June 30, 2025 | | December 31, 2024 | | June 30, 2024 | |
| | | | Amount | % | Amount | % | Amount | % |
| 21XX | Current liabilities | | | | | | | |
| 2100 | Short-term loans | 6(11), 8 | \$ 700,000 | 3 | \$ 1,262,000 | 5 | \$ 375,000 | 1 |
| 2130 | Contract liabilities | 6(18) | 159,938 | 1 | 159,246 | 1 | 122,701 | — |
| 2170 | Accounts payable | | 140,174 | — | 134,790 | — | 130,089 | 1 |
| 2200 | Other payables | 6(12), 7 | 680,787 | 3 | 155,967 | 1 | 1,244,406 | 5 |
| 2230 | Current tax liabilities | 6(22) | 100,950 | — | 277,325 | 1 | 253,223 | 1 |
| 2280 | Lease liabilities | 6(8) | 9,445 | — | 9,214 | — | 9,491 | — |
| 2320 | Long-term liabilities, current portion | 6(11)(13) | 3,708,772 | 16 | 2,595,827 | 10 | 234,854 | 1 |
| 2399 | Other current liabilities | 7 | 18,813 | — | 22,393 | — | 22,589 | — |
| 21XX | Total current liabilities | | <u>5,518,879</u> | <u>23</u> | <u>4,616,762</u> | <u>18</u> | <u>2,392,353</u> | <u>9</u> |
| 25XX | Non-current liabilities | | | | | | | |
| 2500 | Financial liabilities at fair value through profit or loss | 6(2) | 59,690 | — | 46,158 | — | 22,861 | — |
| 2527 | Contract liabilities | 6(18) | 8,521 | — | 4,841 | — | — | — |
| 2530 | Bonds payable | 6(13) | 591,089 | 3 | 2,234,917 | 9 | 4,361,397 | 16 |
| 2540 | Long-term loans | 6(11), 8 | 608,879 | 3 | 419,998 | 2 | 1,323,724 | 5 |
| 2570 | Deferred tax liabilities | 6(22) | 78,612 | — | 148,741 | — | 167,360 | 1 |
| 2580 | Lease liabilities | 6(8) | 3,913 | — | 8,173 | — | 12,506 | — |
| 2670 | Other non-current liabilities | | 3,101 | — | 3,102 | — | 5,576 | — |
| 25XX | Total non-current liabilities | | <u>1,353,805</u> | <u>6</u> | <u>2,865,930</u> | <u>11</u> | <u>5,893,424</u> | <u>22</u> |
| 2XXX | Total liabilities | | <u>6,872,684</u> | <u>29</u> | <u>7,482,692</u> | <u>29</u> | <u>8,285,777</u> | <u>31</u> |
| 31XX | Equity attributable to shareholders of the parent | 6(15) | | | | | | |
| 3110 | Share capital | | 7,249,768 | 31 | 7,249,768 | 28 | 7,181,528 | 26 |
| 3150 | Stock dividends to be distributed | | 362,488 | 1 | — | — | — | — |
| 3200 | Capital surplus | | 4,971,305 | 21 | 5,535,957 | 22 | 5,772,106 | 21 |
| 3300 | Retained earnings | | | | | | | |
| 3310 | Legal reserve | | — | — | 1,267,810 | 5 | 1,267,810 | 5 |
| 3320 | Special reserve | | 5,002,321 | 21 | 5,560,363 | 22 | 5,560,363 | 21 |
| 3350 | Unappropriated earnings | | (94,151) | — | (1,368,634) | (5) | (876,844) | (3) |
| 3400 | Other equity | | | | | | | |
| 3410 | Exchange differences arising on translation of foreign operations | | (117,517) | — | (739) | — | (4,504) | — |
| 3420 | Unrealized gain (loss) on financial assets at fair value through other comprehensive income | | 19,603 | — | 19,603 | — | 74,820 | — |
| 3500 | Treasury shares | | <u>(592,731)</u> | <u>(3)</u> | <u>(209,651)</u> | <u>(1)</u> | <u>(211,493)</u> | <u>(1)</u> |
| 31XX | Total equity attributable to shareholders of the parent | | <u>16,801,086</u> | <u>71</u> | <u>18,054,477</u> | <u>71</u> | <u>18,763,786</u> | <u>69</u> |
| 36XX | Non-controlling interests | 6(15) | <u>6</u> | <u>—</u> | <u>6</u> | <u>—</u> | <u>6</u> | <u>—</u> |
| 3XXX | Total equity | | <u>16,801,092</u> | <u>71</u> | <u>18,054,483</u> | <u>71</u> | <u>18,763,792</u> | <u>69</u> |
| 1XXX | Total liabilities and equity | | <u>\$ 23,673,776</u> | <u>100</u> | <u>\$ 25,537,175</u> | <u>100</u> | <u>\$ 27,049,569</u> | <u>100</u> |

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Comprehensive Income
For the three months and six months ended June 30, 2025 and 2024

| | | | In Thousands of New Taiwan Dollars, Except Earnings Per Share | | | | | | | |
|--------------|--|----------|---|-------|------------|------|--------------------------|------|------------|-------|
| Account Code | Items | Notes | Three Months Ended June 30 | | 2024 | | Six Months Ended June 30 | | 2024 | |
| | | | 2025 | | 2024 | | 2025 | | 2024 | |
| | | | Amount | % | Amount | % | Amount | % | Amount | % |
| 4000 | Net revenue | 6(18) | \$ 378,711 | 100 | \$ 413,419 | 100 | \$ 757,570 | 100 | \$ 776,829 | 100 |
| 5000 | Cost of revenue | | 231,980 | 61 | 222,402 | 54 | 447,581 | 59 | 421,137 | 54 |
| 5900 | Gross profit | | 146,731 | 39 | 191,017 | 46 | 309,989 | 41 | 355,692 | 46 |
| 6000 | Operating expenses | 6(19), 7 | | | | | | | | |
| 6100 | Selling and marketing expenses | | 59,609 | 16 | 61,196 | 15 | 113,467 | 15 | 117,129 | 15 |
| 6200 | General and administrative expenses | | 59,841 | 16 | 56,422 | 13 | 105,646 | 14 | 102,433 | 13 |
| 6300 | Research and development expenses | | 24,444 | 6 | 17,132 | 4 | 42,160 | 6 | 37,841 | 5 |
| 6450 | Expected credit impairment (losses) gains | | (831) | — | 102 | — | (830) | — | 100 | — |
| | Total operating expenses | | 143,063 | 38 | 134,852 | 32 | 260,443 | 35 | 257,503 | 33 |
| 6900 | Income from operations | | 3,668 | 1 | 56,165 | 14 | 49,546 | 6 | 98,189 | 13 |
| 7000 | Non-operating income and expenses | | | | | | | | | |
| 7050 | Finance costs | 6(20), 7 | (53,215) | (14) | (60,004) | (14) | (114,615) | (15) | (114,315) | (15) |
| 7100 | Interest income | | 9,109 | 2 | 23,633 | 6 | 24,685 | 3 | 45,263 | 6 |
| 7130 | Dividend income | | 85,656 | 23 | 87,885 | 21 | 85,656 | 11 | 87,885 | 11 |
| 7190 | Other income | 7 | 9,737 | 2 | 13,161 | 3 | 18,647 | 3 | 26,210 | 3 |
| 7225 | Gain on disposal of investments | | 131,596 | 35 | 8,675 | 2 | 131,630 | 17 | 36,759 | 5 |
| 7230 | (Loss) gain foreign exchange (loss) gain | | (82,717) | (22) | 14,123 | 3 | (67,707) | (9) | 74,442 | 10 |
| 7590 | Other gains and losses | | — | — | (1) | — | (8) | — | (91) | — |
| | Share of profit or loss of associates and joint ventures accounted for using the equity method | | | | | | | | | |
| 7060 | (Loss) on financial assets and liabilities at fair value through profit or loss | 6(6) | (167,143) | (44) | (34,500) | (8) | (275,735) | (36) | (177,885) | (23) |
| 7635 | Total non-operating income and expenses | | (918,816) | (243) | (183,899) | (44) | (266,237) | (35) | (806,449) | (104) |
| 7900 | (Loss) before income tax | | (915,148) | (242) | (127,734) | (30) | (216,691) | (29) | (708,260) | (91) |
| 7950 | Income tax benefit | 6(22) | 188,612 | 50 | 63,788 | 15 | 39,295 | 5 | 95,089 | 12 |
| 8200 | Net income | | (726,536) | (192) | (63,946) | (15) | (177,396) | (24) | (613,171) | (79) |

(To be continued)

(Continued)

| Account Code | Items | Notes | Three Months Ended June 30 | | | | Six Months Ended June 30 | | | |
|-----------------|--|-------|----------------------------|--------------|--------------------|-------------|--------------------------|-------------|---------------------|-------------|
| | | | 2025 | | 2024 | | 2025 | | 2024 | |
| | | | Amount | % | Amount | % | Amount | % | Amount | % |
| 8300 | Other comprehensive income (loss) | | | | | | | | | |
| 8360 | Items that may be reclassified subsequently to profit or loss | 6(21) | | | | | | | | |
| 8361 | Exchange differences arising on translation of foreign operations | | (156,567) | (41) | 10,815 | 3 | (128,994) | (17) | 45,352 | 6 |
| 8370 | Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | | (16,997) | (5) | 3,834 | 1 | (14,471) | (2) | 9,930 | 1 |
| 8399 | Income tax (expense) relating to items that may be reclassified to profit or loss | 6(22) | 32,319 | 9 | (2,183) | (1) | 26,687 | 4 | (9,390) | (1) |
| 8360 | Total components of other comprehensive income that may be reclassified to profit or loss | | (141,245) | (37) | 12,466 | 3 | (116,778) | (15) | 45,892 | 6 |
| 8500 | Total comprehensive income (loss) | | <u>\$ (867,781)</u> | <u>(229)</u> | <u>\$ (51,480)</u> | <u>(12)</u> | <u>\$ (294,174)</u> | <u>(39)</u> | <u>\$ (567,279)</u> | <u>(73)</u> |
| 8600 | Net income (loss) attributable to: | | | | | | | | | |
| 8610 | Shareholders of the parent | | <u>\$ (726,536)</u> | <u>(192)</u> | <u>\$ (72,469)</u> | <u>(17)</u> | <u>\$ (177,396)</u> | <u>(23)</u> | <u>\$ (613,446)</u> | <u>(79)</u> |
| 8620 | Non-controlling interests | | <u>\$ —</u> | <u>—</u> | <u>\$ 8,523</u> | <u>2</u> | <u>\$ —</u> | <u>—</u> | <u>\$ 275</u> | <u>—</u> |
| 8700 | Total comprehensive income attributable to: | | | | | | | | | |
| 8710 | Shareholders of the parent | | <u>\$ (867,781)</u> | <u>(229)</u> | <u>\$ (60,003)</u> | <u>(14)</u> | <u>\$ (294,174)</u> | <u>(39)</u> | <u>\$ (567,554)</u> | <u>(73)</u> |
| 8720 | Non-controlling interests | | <u>\$ —</u> | <u>—</u> | <u>\$ 8,523</u> | <u>2</u> | <u>\$ —</u> | <u>—</u> | <u>\$ 275</u> | <u>—</u> |
| 9750 | Earnings per share Basic earnings (loss) per share | 6(23) | <u>\$ (1.01)</u> | | <u>\$ (0.10)</u> | | <u>\$ (0.25)</u> | | <u>\$ (0.88)</u> | |
| 9850 | Diluted earnings (loss) per share | 6(23) | <u>\$ (1.01)</u> | | <u>\$ (0.10)</u> | | <u>\$ (0.25)</u> | | <u>\$ (0.88)</u> | |

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Changes in Equity
For the six months ended June 30, 2025 and 2024

In Thousands of New Taiwan Dollars

| Items | Equity attributable to shareholders of the parent | | | | | | | | | | | | | | | | | |
|--|---|-----------------------------------|-------------------|---|--|-----------------|----------|---------------|-------------------|-----------------|-------------------------|---|---|-------------|-----------------|---|---------------------------|---------------|
| | Capital surplus | | | | | | | | Retained earnings | | | Other Equity | | | | | | |
| | Share capital | Stock dividends to be distributed | Issued at premium | Difference between consideration and carrying amount of subsidiaries acquired or disposed | Changes in net equity of associates and joint ventures accounted for using the equity method | Treasury shares | Others | Stock options | Legal reserve | Special reserve | Unappropriated earnings | Exchange differences arising on translation of foreign operations | Unrealized gain (loss) on financial assets at fair value through other comprehensive income | Total | Treasury shares | Total equity attributable to shareholders of the parent | Non-controlling interests | Total equity |
| Balance as of January 1, 2024 | \$ 6,914,211 | \$ — | \$ 4,866,544 | \$ 449,327 | \$ 1,046,926 | \$ 76,827 | \$ 1,540 | \$ 800,338 | \$ 1,267,810 | \$ 5,560,363 | \$ (1,004,735) | \$ (50,396) | \$ 74,820 | \$ 24,424 | \$ (246,721) | \$ 19,756,854 | \$ 459,349 | \$ 20,216,203 |
| Issuance of new shares (share exchange) | 248,430 | — | 922,916 | (449,327) | — | — | — | — | — | — | (262,401) | — | — | — | — | 459,618 | (459,618) | — |
| Capital surplus used to offset accumulated deficits | — | — | (1,004,735) | — | — | — | — | — | — | — | 1,004,735 | — | — | — | — | — | — | — |
| Cash dividends from capital surplus | — | — | (1,037,159) | — | — | — | — | — | — | — | — | — | — | — | — | (1,037,159) | — | (1,037,159) |
| Conversion of convertible bonds to issuance of new shares | 18,887 | — | 65,896 | — | — | — | — | (16,317) | — | — | — | — | — | — | — | 68,466 | — | 68,466 |
| Other changes in capital surplus | | | | | | | | | | | | | | | | | | |
| Adjustments to share of changes in equities of associates | — | — | — | — | 44,651 | — | — | — | — | — | (997) | — | — | — | — | 43,654 | — | 43,654 |
| Recovery of unclaimed dividends from shareholders | — | — | — | — | — | — | 69 | — | — | — | — | — | — | — | — | 69 | — | 69 |
| Disposal of the parent company's share by subsidiaries recognized as treasury share transactions | — | — | — | — | — | 4,610 | — | — | — | — | — | — | — | — | 35,228 | 39,838 | — | 39,838 |
| Net income (loss) | — | — | — | — | — | — | — | — | — | — | (613,446) | — | — | — | — | (613,446) | 275 | (613,171) |
| Other comprehensive income | — | — | — | — | — | — | — | — | — | — | — | 45,892 | — | 45,892 | — | 45,892 | — | 45,892 |
| Balance as of June 30, 2024 | \$ 7,181,528 | \$ — | \$ 3,813,462 | \$ — | \$ 1,091,577 | \$ 81,437 | \$ 1,609 | \$ 784,021 | \$ 1,267,810 | \$ 5,560,363 | \$ (876,844) | \$ (4,504) | \$ 74,820 | \$ 70,316 | \$ (211,493) | \$ 18,763,786 | \$ 6 | \$ 18,763,792 |
| Balance as of January 1, 2025 | \$ 7,249,768 | \$ — | \$ 4,054,144 | \$ — | \$ 665,876 | \$ 88,455 | \$ 1,609 | \$ 725,873 | \$ 1,267,810 | \$ 5,560,363 | \$ (1,368,634) | \$ (739) | \$ 19,603 | \$ 18,864 | \$ (209,651) | \$ 18,054,477 | \$ 6 | \$ 18,054,483 |
| Cash dividends from capital surplus | — | — | (543,732) | — | — | — | — | — | — | — | — | — | — | — | — | (543,732) | — | (543,732) |
| Appropriation of earnings: | | | | | | | | | | | | | | | | | | |
| Stock dividends | — | 362,488 | — | — | — | — | — | — | — | — | (362,488) | — | — | — | — | — | — | — |
| Legal reserve used to offset accumulated deficits | — | — | — | — | — | — | — | — | (1,267,810) | — | 1,267,810 | — | — | — | — | — | — | — |
| Reversal of special reserve | — | — | — | — | — | — | — | — | — | (558,042) | 558,042 | — | — | — | — | — | — | — |
| Other changes in capital surplus | | | | | | | | | | | | | | | | | | |
| Adjustments to share of changes in equities of associates | — | — | — | — | (24,535) | — | — | — | — | — | (11,485) | — | — | — | — | (36,020) | — | (36,020) |
| Recovery of unclaimed dividends from shareholders | — | — | — | 21 | — | — | 47 | — | — | — | — | — | — | — | — | 68 | — | 68 |
| Repurchase of treasury shares | — | — | — | — | — | — | — | — | — | — | — | — | — | — | (383,080) | (383,080) | — | (383,080) |
| Net income (loss) | — | — | — | — | — | — | — | — | — | — | (177,396) | — | — | — | — | (177,396) | — | (177,396) |
| Other comprehensive income | — | — | — | — | — | — | — | — | — | — | — | (116,778) | — | (116,778) | — | (116,778) | — | (116,778) |
| Share-based compensation | — | — | — | — | — | — | — | 3,547 | — | — | — | — | — | — | — | 3,547 | — | 3,547 |
| Balance as of June 30, 2025 | \$ 7,249,768 | \$ 362,488 | \$ 3,510,412 | \$ 21 | \$ 641,341 | \$ 88,455 | \$ 1,656 | \$ 729,420 | \$ — | \$ 5,002,321 | \$ (94,151) | \$ (117,517) | \$ 19,603 | \$ (97,914) | \$ (592,731) | \$ 16,801,086 | \$ 6 | \$ 16,801,092 |

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the six months ended June 30, 2025 and 2024

| | | In Thousands of New Taiwan Dollars | |
|--|----|---|------------------|
| | | Six Months Ended June 30 | |
| | | 2025 | 2024 |
| Cash flows from operating activities: | | | |
| (Loss) before income tax | \$ | (216,691) | \$ (708,260) |
| Adjustments for: | | | |
| The income or loss items which did not affect cash flows | | | |
| Depreciation expense | | 58,843 | 53,776 |
| Amortization expense | | 25,173 | 24,404 |
| Share-based compensation | | 3,547 | — |
| Net loss on financial assets and liabilities at fair value through profit or loss | | 68,790 | 784,717 |
| Loss (gain) on disposal of property, plant and equipment | | 1 | (68) |
| Expected credit (gains) losses | | (830) | 100 |
| Unrealized foreign exchange loss (gain) | | 18,512 | (25,575) |
| Interest expense | | 114,615 | 114,315 |
| Interest income | | (24,685) | (45,263) |
| Dividend income | | (85,656) | (87,885) |
| Share of profit or loss of associates and joint ventures accounted for using the equity method | | 275,735 | 177,885 |
| Gain on disposal of investments | | (131,630) | (36,759) |
| Current transfer expenses of construction in process | | 2,724 | — |
| Changes in operating assets and liabilities | | | |
| Decrease in notes receivable | | 4,353 | 17,994 |
| (Increase) decrease in accounts receivable | | (22,403) | 4,077 |
| Decrease in other receivables | | 1,230 | 8,865 |
| (Increase) in inventories | | (6,051) | (3,449) |
| (Increase) decrease in other current assets | | (1,340) | 3,417 |
| (Increase) in defined benefit asset, net | | (1,493) | (1,300) |
| Increase (decrease) in accounts payable | | 5,384 | (14,553) |
| (Decrease) in other payables | | (13,001) | (25,562) |
| Increase in contract liabilities | | 4,372 | 9,035 |
| (Decrease) increase in other current liabilities | | (3,580) | 543 |
| Cash generated from operations | | <u>75,919</u> | <u>250,454</u> |
| Interest received | | 27,711 | 47,443 |
| Interest paid | | (38,728) | (48,547) |
| Income tax paid | | <u>(179,049)</u> | <u>(141,270)</u> |
| Net cash (used in) provided by operating activities | | <u>(114,147)</u> | <u>108,080</u> |

(To be continued)

(Continued)

| | Six Months Ended June 30 | |
|---|---------------------------------|--------------|
| | 2025 | 2024 |
| Cash flows from investing activities: | | |
| Acquisition of financial assets at fair value through profit or loss | (151,364) | (1,279,709) |
| Proceeds from disposal of financial assets at fair value through profit or loss | 193,256 | 392,338 |
| Acquisition of investments accounted for using the equity method | (14,612) | (80,180) |
| Proceeds from disposal of investments accounted for using the equity method | 145,813 | 41,186 |
| Acquisition of intangible assets | (1,876) | (2,411) |
| Acquisition of property, plant and equipment (Including prepayment for equipment) | (106,269) | (93,506) |
| Proceeds from disposal of property, plant and equipment | — | 150 |
| Decrease in financial assets at amortized cost | 155,066 | 386,235 |
| Decrease in refundable deposits | 582 | 1,607 |
| Decrease (increase) in other financial assets | 1,115 | (98,521) |
| Dividends received | 154,024 | 88,513 |
| Net cash provided by (used in) investing activities | 375,735 | (644,298) |
| Cash flows from financing activities: | | |
| (Decrease) increase in short-term loans | (562,000) | 45,000 |
| (Repayment of) proceeds from long-term loans | (415,519) | 644,596 |
| Repayment of the principal portion of lease liabilities | (4,738) | (4,572) |
| Recovery of unclaimed dividends from shareholders | 68 | 83,161 |
| Repurchase of treasury shares | (383,080) | — |
| Proceeds from disposal of treasury stock | — | 39,838 |
| Net cash (used in) provided by financing activities | (1,365,269) | 808,023 |
| Effect of exchange rate changes on cash and cash equivalents | (973) | 304 |
| Net (decrease) increase in cash and cash equivalents | (1,104,654) | 272,109 |
| Cash and cash equivalents, beginning of period | 1,442,273 | 1,704,592 |
| Cash and cash equivalents, end of period | \$ 337,619 | \$ 1,976,701 |

(The accompanying notes are an integral part of the consolidated financial statements.)

Center Laboratories, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

For the Six Months Ended June 30, 2025 and 2024

(Expressed in New Taiwan Dollars, Unless Specified Otherwise)

1. GENERAL INFORMATION

Center Laboratories, Inc. (hereinafter referred to as “the Company”) was established on November 4, 1959 in accordance with the Company Act. As of June 30, 2025, the Company possessed an authorized capital of \$10,000,000 thousand and a paid-in capital of \$7,249,768 thousand. The Company mainly engages in the manufacture and sale of various Western medicines. The Company and its factories are located in Taipei City and Hsinchu County, Taiwan, respectively.

The Company’s shares have been traded on Taipei Exchange since October 2003.

2. THE AUTHORIZATION OF FINANCIAL STATEMENTS

The consolidated financial statements of the Company have been released after submission to the Board of Directors on August 12, 2025.

3. APPLICATION OF NEW AND REVISED STANDARDS AND INTERPRETATIONS

(1) Initial adoption of the International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), International Financial Reporting Interpretations Committee (IFRIC), and Standard Interpretations Committee (SIC) (hereinafter referred to as the “IFRSs”) endorsed and promulgated by the Financial Supervisory Commission (the “FSC”).

The adoption of the revised IFRSs approved and issued by the Financial Supervisory Commission, effective from January 1, 2025, is not expected to result in significant changes to the accounting policies of the consolidated company.

(2) IFRSs issued by IASB but not yet endorsed and announced by the FSC:

| New, Revised or Amended Standards and Interpretations | Effective Date of Issuance by the IASB (Note 1) |
|---|---|
| Annual Improvements to IFRSs - Volume 11 | January 1, 2026 |
| Amendments to IFRS 9 and IFRS 7 “Amendments to the Classification and Measurement of Financial Instruments” | January 1, 2026 |
| Amendment to IFRS 9 and IFRS 7 “Contracts Referencing Nature-dependent Electricity” | January 1, 2026 |

| New, Revised or Amended Standards and Interpretations | Effective Date of Issuance by the IASB (Note 1) |
|---|---|
| Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between an Investor and its Associate or Joint Venture” | To be determined by IASB. |
| IFRS 18 “Presentation and Disclosure in Financial Statements” | January 1, 2027 |
| IFRS 19 “Subsidiaries without Public Accountability: Disclosure” | January 1, 2027 |
| Note 1: Unless stated otherwise, the aforementioned new, revised and amended standards and interpretations are effective for annual reporting periods beginning on or after the respective effective dates. | |

In the future, the consolidated company adopts the above IASB standards or interpretations which have not yet been accredited by the FSC and those may have a potential impact on the consolidated company’s financial statements are as follows:

A. IFRS 18 “Presentation and Disclosure in Financial Statements”

IFRS 18 will replace IAS 1 “Presentation of Financial Statements”. The main changes in this standard include:

The income statement should classify revenue and expense items by operating, investing, financing, income tax, and discontinued operations categories.

The income statement should present operating profit or loss, profit or loss before financing and income tax, and subtotals and totals of profit or loss.

Providing guidance to enhance aggregation and disaggregation requirements: Consolidated entities must identify assets, liabilities, equity, income, expenses, and cash flows arising from individual transactions or other events and classify and aggregate them based on common characteristics, ensuring that each significant line item in the primary financial statements has at least one similar characteristic. Items with different characteristics should be disaggregated in the primary financial statements and notes. Consolidated entities should only label such items as “other” when more informative names cannot be found.

Adding disclosures on performance measures defined by management: Consolidated entities should disclose relevant information on performance measures defined by management in a single note to the financial statements when engaging in external communication beyond financial statements and when communicating management’s perspective on a particular aspect of the consolidated entity’s overall financial performance to users of the financial statements. This disclosure should include a description of the measure, how it is calculated, adjustments to subtotals or totals defined in IFRS accounting standards, and the tax and non-controlling interest effects of related adjustments.

As of the date the consolidated financial statements are authorized for issue, the Consolidated Company is continuously assessing the impact of other standards and amendments of interpretation on its financial position and financial performance, and will disclose the relevant impact upon completion of the assessment.

4. **SUMMARY OF MATERIAL ACCOUNTING POLICIES**

Apart from the following explanation, the significant accounting policies adopted in this consolidated financial report are consistent with those of the 2024 consolidated financial report. For further information, please refer to Note 4 of the 2024 consolidated financial report.

(1) Statement of Compliance

This consolidated financial statements have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers (hereinafter referred to as the “Regulations”) and IAS 34 “Interim Financial Reporting” as recognized and issued by the Financial Supervisory Commission. This consolidated financial report does not include all the necessary information required to be disclosed in the entire annual consolidated financial statements prepared in accordance with the International Financial Reporting Standards, International Accounting Standards, Interpretations, and Interpretation Bulletins as recognized and issued by the Financial Supervisory Commission.

(2) Basis of Preparation

Except for financial instruments measured by fair value, the consolidated financial statements are prepared on a historical cost basis. Historical cost is usually based on the fair value of the consideration paid to acquire the asset.

(3) Basis of Preparation for Consolidated Financial Statements

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries). Control refers to the Company’s power to direct the financial and operating policies of an individual to obtain benefits from its related operating activities.

The consolidated income statement has Income and expenses of subsidiaries acquired or disposed of are included in the consolidated statement of comprehensive income from the effective date of acquisition and up to the effective date of disposal, as appropriate. The total comprehensive income of subsidiaries is attributed to the Company’s shareholders and non-controlling interests, even if this results in non-controlling interests having a deficit balance.

When necessary, adjustments are made to subsidiaries’ financial statements to bring their accounting policies into line with those used by the Company.

All significant transactions, balances, income, and expenses between the Company's consolidated entities are eliminated in full on consolidation.

Changes in the Company's ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. The carrying amounts of the Company's interests and the non-controlling interests are adjusted to reflect changes in their relative interests in the subsidiaries. Any difference between the amount by which the non-controlling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the Company's shareholders.

When the consolidated company loses control of the subsidiary, the disposition gains and losses are the difference between the following two; (1) The fair value of the consideration received and the remaining investment in the former subsidiary is counted at the fair value on the day when the control was lost, and (2) The assets (including goodwill), liabilities, and non-controlling interests of the former subsidiary are counted based on the book value on the date of loss of control. The consolidated company recognizes all amounts related to the subsidiary in other comprehensive profits and losses, and its accounting treatment is based on the same basis that the consolidated company must follow when directly processing related assets or liabilities.

The former subsidiary's remaining investment is based on the fair value at the date of loss of control as the amount initially recognized for investment in the affiliated Company.

A. The subsidiaries included in the preparation of the consolidated financial statements are listed as follows:

| Name of Investor | Name of Subsidiary | Relationship with the Company | Nature of Business | Percentage of Ownership/Capital Contribution | | |
|--|---------------------------------------|-------------------------------|--------------------|--|-------------------|---------------|
| | | | | June 30, 2025 | December 31, 2024 | June 30, 2024 |
| The Company | Center Biotherapeutics Inc. | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company | Centerlab Investment Holding Limited | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company | BioEngine Technology Development Inc. | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company and Centerlab Investment Holding Limited | Bioflag International Corporation | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| Bioflag International Corporation | Bioflag Co., Ltd. | Sub-subsidiary of the Company | Investment | — | 100.00% | 100.00% |

| Name of Investor | Name of Subsidiary | Relationship with the Company | Nature of Business | Percentage of Ownership/Capital Contribution | | |
|--|--|-------------------------------|---|--|-------------------|---------------|
| | | | | June 30, 2025 | December 31, 2024 | June 30, 2024 |
| Bioflag International Corporation | Glac Biotech Co., Ltd. | Sub-subsidiary of the Company | Manufacturing and Sales of Functional Probiotics | 100.00% | — | — |
| Bioflag Co., Ltd. | Genlac Biotech Inc. | Sub-subsidiary of the Company | Investment | — | — | 100.00% |
| Bioflag Co., Ltd. or Genlac Biotech Inc. | Glac Biotech Co., Ltd. | Sub-subsidiary of the Company | Manufacturing and Sales of Functional Probiotics | — | 100.00% | 100.00% |
| Glac Biotech Co., Ltd. | OmniPro Biotech Co., Ltd. | Sub-subsidiary of the Company | General Food Manufacturing | 100.00% | 100.00% | 100.00% |
| Glac Biotech Co., Ltd. | Ezadd Co., Ltd. | Sub-subsidiary of the Company | Functional Probiotics Sales | 99.50% | 99.50% | 99.50% |
| The Company | Center Laboratories Limited | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company | Center Venture Holding I Limited | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company | Center Venture Holding II Limited | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| The Company | Center Venture Holding III Limited | A subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| BioEngine Technology Development Inc. | BioEngine Development I Limited | Sub-subsidiary of the Company | Investment | 100.00% | 100.00% | 100.00% |
| BioEngine Development I Limited | Beijing Shundu Pharmaceutical Research Institute Co., Ltd. | Sub-subsidiary of the Company | Research and Development of New Pharmaceuticals and Skincare Products | 100.00% | 100.00% | 100.00% |

B. The important changes in the consolidated entities are explained as follows:

- (a) In May 2024, the Company acquired 52.67% of the shares of Bioflag International Corporation through the issuance of new shares. After the share exchange, Bioflag International Corporation became a wholly-owned subsidiary of the Company.
- (b) Genlac Biotech Inc. was dissolved in September 2024 and completed its liquidation in November of the same year. Its original investment in Glac Biotech Co., Ltd. is now directly held by Bioflag Co., Ltd.
- (c) Bioflag Co., Ltd. completed its dissolution and liquidation procedures in May 2025. The investment originally held by Glac Biotech Co., Ltd. is now directly held by Bioflag International Corporation.

(4) Income Tax

The Group measures and discloses income tax expense for interim periods in accordance with paragraph B12 of IAS 34 “Interim Financial Reporting”.

Income tax expense is measured by applying the best estimate of the applicable tax rate for the expected annual total earnings of the management multiplied by the pre-tax net profit for the interim reporting period, and is fully recognized as the current income tax expense.

Income tax expense that is directly recognized in equity items or other comprehensive income items is measured based on the temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their tax bases, using the applicable tax rates expected to be realized or settled upon.

(5) Defined benefit post-employment benefits

Pension cost for the interim period is calculated on a year-to-date basis using the actuarially determined pension cost rate as of the prior year-end date, adjusted for significant market fluctuations during the period and significant plan amendments, settlements or other significant one-time events.

5. MATERIAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION AND UNCERTAINTY

The preparation of these consolidated financial statements in conformity with the Regulations and IAS 34, “Interim Financial Reporting,” as endorsed by the FSC, requires management to make judgments, estimates and assumptions that affect the adoption of accounting policies and the reported amounts of assets, liabilities, revenues and expenses. Actual results may differ from the estimates.

Estimates and fundamental assumptions are regularly reviewed. If a revision of the estimate only impacts the current period, it is reflected in the accounting estimate revision for that period. If the revision of the accounting estimate affects both the current period and future periods, it is reflected in the estimate revision for both the current and future periods.

When preparing the consolidated financial statements, the significant judgments made by management in the adoption of accounting policies for consolidation and the principal sources of estimation uncertainty are consistent with Note 5 of the 2024 consolidated financial statements.

6. DESCRIPTION OF SIGNIFICANT ACCOUNTS

(1) Cash and cash equivalents

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---------------------------------------|-------------------|---------------------|---------------------|
| Cash on hand and petty cash | \$ 557 | \$ 505 | \$ 504 |
| Checking accounts and demand deposits | 330,100 | 798,046 | 1,849,249 |
| Cash equivalents: | | | |
| Time deposits | 6,962 | 643,722 | 126,948 |
| Total | <u>\$ 337,619</u> | <u>\$ 1,442,273</u> | <u>\$ 1,976,701</u> |

A. Equivalent cash includes time deposits that are highly liquid, convertible into fixed cash at any time and have little risk of price changes within 3 months from the date of acquisition, and are used to meet short-term cash commitments.

B. Cash and cash equivalents described above have not been pledged as collateral.

(2) Financial instruments at fair value through profit or loss

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|----------------------|----------------------|----------------------|
| Financial assets - current | | | |
| Designated to be measured at fair value through profit or loss | | | |
| Foreign listed stocks | <u>\$ 304,961</u> | <u>\$ 257,998</u> | <u>\$ 302,637</u> |
| Financial assets - non-current | | | |
| Designated to be measured at fair value through profit or loss | | | |
| Domestic listed stocks | \$ 2,229,552 | \$ 2,567,288 | \$ 3,263,963 |
| Domestic unlisted ordinary shares and emerging stocks | 185,418 | 192,667 | 197,315 |
| Foreign listed stocks | 2,176,318 | 1,351,278 | 1,595,857 |
| Equity shares of unlisted foreign companies | 934,369 | 1,060,446 | 1,082,360 |
| Foreign unlisted preference/ordinary shares | 3,014,413 | 3,439,016 | 2,391,949 |
| Foreign funds | 4,342,700 | 4,434,912 | 4,427,444 |
| Derivative financial instruments - Redemption Rights | 1,355 | 3,117 | 8,990 |
| Total | <u>\$ 12,884,125</u> | <u>\$ 13,048,724</u> | <u>\$ 12,967,878</u> |
| Financial liabilities - non-current | | | |
| Designated to be measured at fair value through profit or loss | | | |
| Derivative financial instruments - put options | <u>\$ 59,690</u> | <u>\$ 46,158</u> | <u>\$ 22,861</u> |

- A. The Company has issued convertible corporate bonds, which consist of principal contract debt instruments and put option derivative instruments. Put option derivatives are valued at fair value and reported as profit or loss.
- B. Please refer to Note 8 for the details that the Company provides financial assets as collateral for bank loans.

(3) Financial assets at amortized cost

| Item | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|---------------|-------------------|---------------|
| Current item: | | | |
| Time deposits with original maturity period of more than three months | \$ 176,431 | \$ 350,009 | \$ 384,857 |

- A. The ranges of market interest rates on time deposits at the balance sheet date are listed as follows:

| Item | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---------------|---------------|-------------------|---------------|
| Time deposits | 1.47%~4.33% | 3.0%~4.57% | 5.26%~5.40% |

(4) Accounts receivable, net

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|---------------|-------------------|---------------|
| Measured at amortized cost | | | |
| Accounts receivable from general customers | \$ 202,756 | \$ 180,354 | \$ 188,037 |
| Less: Loss allowance | (1,272) | (1,775) | (1,603) |
| Net | \$ 201,484 | \$ 178,579 | \$ 186,434 |

None of the accounts receivable above has been pledged as collateral.

The consolidated company estimates expected credit losses for all accounts receivable using a simplified approach, i.e. measurement of lifetime expected credit losses. For the purpose of measurement, expected credit loss rate is determined based on the number of days on which an account receivable is recorded, and is included in forward-looking information. The analysis of expected credit losses for accounts receivable as of June 30, 2025, December 31, 2024, and June 30, 2024, is as follows:

June 30, 2025

| Age | Carrying Amount of Accounts Receivable | Allowance for Lifetime Expected Credit Losses |
|----------------------|---|--|
| Within 90 days | \$ 178,825 | \$ 294 |
| 90 days to 180 days | 22,424 | 312 |
| 180 days to 365 days | 1,189 | 348 |
| Over 365 days | 318 | 318 |
| Total | <u>\$ 202,756</u> | <u>\$ 1,272</u> |

December 31, 2024

| Age | Carrying Amount of Accounts Receivable | Allowance for Lifetime Expected Credit Losses |
|----------------------|---|--|
| Within 90 days | \$ 158,465 | \$ 408 |
| 90 days to 180 days | 20,289 | 370 |
| 180 days to 365 days | 1,281 | 678 |
| Over 365 days | 319 | 319 |
| Total | <u>\$ 180,354</u> | <u>\$ 1,775</u> |

June 30, 2024

| Age | Carrying Amount of Accounts Receivable | Allowance for Lifetime Expected Credit Losses |
|----------------------|---|--|
| Within 90 days | \$ 164,888 | \$ 531 |
| 90 days to 180 days | 21,512 | 524 |
| 180 days to 365 days | 1,604 | 515 |
| Over 365 days | 33 | 33 |
| Total | <u>\$ 188,037</u> | <u>\$ 1,603</u> |

Information on changes in allowance for bad debt arising from accounts receivable is listed as follows:

| Items | June 30, 2025 | June 30, 2024 |
|--|-----------------|-----------------|
| Beginning balance | \$ 1,775 | \$ 1,953 |
| Recognition (reversal) of impairment loss | (503) | 105 |
| Written-off as uncollectible | — | (455) |
| Ending balance | <u>\$ 1,272</u> | <u>\$ 1,603</u> |

(5) Inventories

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|-------------------|----------------------|-------------------|
| Merchandise inventories | \$ 470 | \$ 389 | \$ 268 |
| Finished goods | 162,837 | 156,365 | 148,933 |
| Work-in-progress and semi-finished goods | 57,671 | 44,745 | 39,698 |
| Raw materials | 101,036 | 103,046 | 81,324 |
| Supplies | 14,960 | 12,194 | 23,190 |
| Inventories in transit | 5,388 | 19,236 | 4,217 |
| Total | <u>\$ 342,362</u> | <u>\$ 335,975</u> | <u>\$ 297,630</u> |
| Less: Allowance for inventory valuation losses | (26,608) | (26,272) | (24,953) |
| Net | <u>\$ 315,754</u> | <u>\$ 309,703</u> | <u>\$ 272,677</u> |

Costs of goods sold for the six months ended June 30, 2024 and 2025 include diminution in value of inventory (gain from price recovery) amounting to \$336 thousand and 1,857 thousand, respectively.

(6) Investments accounted for using the equity method

| Item | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---------------------------|---------------|-------------------|---------------|
| Investments in associates | \$ 5,236,463 | \$ 5,761,850 | \$ 5,868,705 |

A. Investments in associates are detailed as follows:

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|---------------|-------------------|---------------|
| Material associates | | | |
| Medeon Biodesign, Inc. | \$ 313,756 | \$ 452,226 | \$ 572,799 |
| TOT BIOPHARM International Company Limited | 2,883,503 | 2,983,726 | 2,976,401 |
| Mycenax Biotech Inc. | 372,963 | 426,073 | 461,058 |
| Lumosa Therapeutics Co., Ltd. | 568,409 | 668,841 | 459,935 |
| | 4,138,631 | 4,530,866 | 4,470,193 |
| Individually immaterial associates | 1,097,832 | 1,230,984 | 1,398,512 |
| Total | \$ 5,236,463 | \$ 5,761,850 | \$ 5,868,705 |

B. The basic information of associates that are material to the Group is listed as follows:

| Items | Shareholding ratio | | |
|--|--------------------|-------------------|---------------|
| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
| Medeon Biodesign, Inc. | 28.42% | 29.75% | 29.75% |
| TOT BIOPHARM International Company Limited | 28.59% | 28.59% | 28.59% |
| Mycenax Biotech Inc. | 20.64% | 20.65% | 20.39% |
| Lumosa Therapeutics Co., Ltd. | 34.97% | 34.83% | 33.40% |

For information on the nature of business, principal place of business, and country of registration of the associates above, please refer to Table 2 “Information on Investees” and Table 3 “Information on Investment in Mainland China.”

- C. Information on the Level 1 fair value measurements of associates with quoted prices in active markets is provided as follows:

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|----------------------|----------------------|----------------------|
| Medeon Biodesign, Inc. | \$ 3,343,054 | \$ 1,086,847 | \$ 1,397,962 |
| TOT BIOPHARM International Company Limited | 1,616,246 | 1,669,864 | 2,010,596 |
| Mycenax Biotech Inc. | 639,771 | 693,285 | 942,485 |
| Lumosa Therapeutics Co., Ltd. | 6,111,554 | 10,407,523 | 8,906,923 |
| Individually immaterial associates | 1,133,037 | 1,264,567 | 1,475,015 |
| Total | <u>\$ 12,843,662</u> | <u>\$ 15,122,086</u> | <u>\$ 14,732,981</u> |

- D. For the amount of investments in associates pledged by the Company as collateral for borrowings, please refer to Note 8.
- E. The summary financial information of the material associates below is provided according to the consolidated financial statements of each associate prepared based on IFRSs, and has reflected adjustments made thereto using the equity method.

Balance Sheets

| | June 30, 2025 | | | |
|---|------------------------|--|----------------------|-------------------------------|
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Current assets | \$ 917,837 | \$ 3,054,967 | \$ 706,054 | \$ 1,199,666 |
| Non-current assets | 499,285 | 3,490,780 | 2,508,867 | 552,913 |
| Current liabilities | 182,341 | 1,458,413 | 841,505 | 119,991 |
| Non-current liabilities | 102,187 | 1,588,318 | 606,602 | 3,478 |
| Equity | 1,132,594 | 3,499,016 | 1,766,814 | 1,629,110 |
| Non-controlling interests | (28,741) | — | — | (12,556) |
| | <u>\$ 1,103,853</u> | <u>\$ 3,499,016</u> | <u>\$ 1,766,814</u> | <u>\$ 1,616,554</u> |
| The Company's share of profit | \$ 313,756 | \$ 1,000,450 | \$ 364,714 | \$ 565,373 |
| Goodwill | — | 1,883,053 | 8,249 | 11,031 |
| Downstream/sides tream transactions with associates | — | — | — | (7,995) |
| Carrying amount of associates invested | <u>\$ 313,756</u> | <u>\$ 2,883,503</u> | <u>\$ 372,963</u> | <u>\$ 568,409</u> |

| December 31, 2024 | | | | |
|--|---------------------------|--|-------------------------|-------------------------------------|
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Current assets | \$ 1,317,199 | \$ 3,328,394 | \$ 736,381 | \$ 1,537,047 |
| Non-current assets | 560,544 | 4,010,027 | 2,631,995 | 595,914 |
| Current liabilities | 215,642 | 1,859,996 | 661,496 | 201,176 |
| Non-current liabilities | 126,198 | 1,628,890 | 683,401 | 4,281 |
| Equity | 1,535,903 | 3,849,535 | 2,023,479 | 1,927,504 |
| Non-controlling interests | (15,711) | — | — | (15,835) |
| | <u>\$ 1,520,192</u> | <u>\$ 3,849,535</u> | <u>\$ 2,023,479</u> | <u>\$ 1,911,669</u> |
| The Company's share of profit | \$ 452,226 | \$ 1,100,673 | \$ 417,824 | \$ 665,886 |
| Goodwill | — | 1,883,053 | 8,249 | 11,031 |
| Downstream/sides tream transactions with associates | — | — | — | (8,076) |
| Carrying amount of associates invested | <u>\$ 452,226</u> | <u>\$ 2,983,726</u> | <u>\$ 426,073</u> | <u>\$ 668,841</u> |
| June 30, 2024 | | | | |
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Current assets | \$ 1,729,809 | \$ 3,201,822 | \$ 985,817 | \$ 807,761 |
| Non-current assets | 569,608 | 3,879,242 | 2,645,002 | 788,526 |
| Current liabilities | 187,758 | 1,653,687 | 638,368 | 197,305 |
| Non-current liabilities | 154,291 | 1,603,463 | 764,578 | 6,390 |
| Equity | 1,957,368 | 3,823,914 | 2,227,873 | 1,392,592 |
| Non-controlling interests | (31,863) | — | — | (24,226) |
| | <u>\$ 1,925,505</u> | <u>\$ 3,823,914</u> | <u>\$ 2,227,873</u> | <u>\$ 1,368,366</u> |
| The Company's share of profit | \$ 572,799 | \$ 1,093,348 | \$ 452,809 | \$ 457,066 |
| Goodwill | — | 1,883,053 | 8,249 | 11,031 |
| Downstream/sides tream transactions with associates | — | — | — | (8,162) |
| Carrying amount of associates invested | <u>\$ 572,799</u> | <u>\$ 2,976,401</u> | <u>\$ 461,058</u> | <u>\$ 459,935</u> |

Statements of Comprehensive Income

| Three Months Ended June 30, 2025 | | | | |
|--|---------------------------|--|-------------------------|-------------------------------------|
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Revenue | \$ 110,382 | \$ 1,016,721 | \$ 202,559 | \$ 2,810 |
| Net income of continuing operations | \$ (188,312) | \$ 8,454 | \$ (137,162) | \$ (149,978) |
| Other comprehensive income (net after tax) | (39,256) | (17,582) | (559) | (140) |
| Total comprehensive income (loss) | \$ (227,568) | \$ (9,128) | \$ (137,721) | \$ (150,118) |
| Dividends received from associates | \$ — | \$ — | \$ — | \$ — |
| Six Months Ended June 30, 2025 | | | | |
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Revenue | \$ 212,260 | \$ 2,155,298 | \$ 324,275 | \$ 11,706 |
| Net income of continuing operations | \$ (378,850) | \$ 17,898 | \$ (266,299) | \$ (255,381) |
| Other comprehensive income (net after tax) | (34,904) | (15,532) | (500) | (112) |
| Total comprehensive income (loss) | \$ (413,754) | \$ 2,366 | \$ (266,799) | \$ (255,493) |
| Dividends received from associates | \$ — | \$ — | \$ — | \$ — |

| Three Months Ended June 30, 2024 | | | | |
|---|------------------------------|--|-------------------------|-------------------------------------|
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Revenue | \$ 63,526 | \$ 1,325,345 | \$ 200,611 | \$ 8,516 |
| Net income of continuing operations | \$ (228,763) | \$ 106,897 | \$ (101,616) | \$ 65,635 |
| Other comprehensive income (net after tax) | 5,116 | 3,070 | 69 | 12 |
| Total comprehensive income (loss) | \$ (223,647) | \$ 109,967 | \$ (101,547) | \$ 65,647 |
| Dividends received from associates | \$ — | \$ — | \$ — | \$ — |
| Six Months Ended June 30, 2024 | | | | |
| | Medeon Biodesign, Inc. | TOT BIOPHARM International Company Limited | Mycenax Biotech Inc. | Lumosa Therapeutics Co., Ltd. |
| Revenue | \$ 110,667 | \$ 2,297,057 | \$ 280,801 | \$ 12,979 |
| Net income of continuing operations | \$ (443,276) | \$ 139,248 | \$ (237,227) | \$ (51,956) |
| Other comprehensive income (net after tax) | 18,634 | 6,720 | 229 | 37 |
| Total comprehensive income (loss) | \$ (424,642) | \$ 145,968 | \$ (236,998) | \$ (51,919) |
| Dividends received from associates | \$ — | \$ — | \$ — | \$ — |

- F. The carrying amounts and share of operating results of the Group's individually immaterial associates are summarized as follows:

As of June 30, 2025, December 31, 2024, and June 30, 2024, the total book value of other affiliated enterprises of the Group amounted to NT\$1,097,832 thousand, NT\$1,230,984 thousand, and NT\$1,398,512 thousand, respectively.

| The Company's share of profit | Three Months Ended June 30 | |
|--|----------------------------|----------|
| | 2025 | 2024 |
| Net income of continuing operations | \$ (32,733) | \$ 451 |
| Other comprehensive income (net after tax) | \$ (311) | \$ 1,478 |

| The Company's share of profit | Six Months Ended June 30 | |
|--|--------------------------|-------------|
| | 2025 | 2024 |
| Net income of continuing operations | \$ (23,989) | \$ (22,275) |
| Other comprehensive income (net after tax) | \$ (43) | \$ 2,605 |

(7) Property, plant and equipment

- A. The carrying amounts of the Group's property, plant, and equipment are listed as follows:

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|---------------|-------------------|---------------|
| Land, buildings, and facilities | \$ 785,535 | \$ 775,110 | \$ 772,516 |
| Machinery and equipment | 434,620 | 379,542 | 357,524 |
| Transportation equipment | 1,469 | 1,727 | 1,607 |
| Office equipment | 51,053 | 54,066 | 44,220 |
| Leasehold improvements | 118,973 | 100,899 | 108,367 |
| Miscellaneous equipment | 39,263 | 27,808 | 28,596 |
| Construction in progress and equipment under installation | 32,584 | 76,768 | 28,374 |
| Total | \$ 1,463,497 | \$ 1,415,920 | \$ 1,341,204 |

B. Changes in cost, depreciation, and impairment loss on the Group's property, plant, and equipment are detailed as follows:

| | Balance as of January 1, 2025 | Additions - individually acquired | Disposals | Reclassification | Effect of exchange differences | Balance as of June 30, 2025 |
|---|----------------------------------|---|-------------------|------------------|--------------------------------------|--------------------------------|
| Cost: | | | | | | |
| Land, buildings, and facilities | \$ 1,016,898 | \$ 8,245 | \$ — | \$ 13,792 | \$ — | \$ 1,038,935 |
| Machinery and equipment | 748,006 | 29,193 | — | 49,517 | (60) | 826,656 |
| Transportation equipment | 5,716 | — | — | — | — | 5,716 |
| Office equipment | 156,525 | 3,179 | (1,596) | — | — | 158,108 |
| Leasehold improvements | 137,863 | 11,553 | — | 14,773 | — | 164,189 |
| Miscellaneous equipment | 60,245 | 2,797 | (1,099) | 10,912 | — | 72,855 |
| Construction in progress and equipment under installation | 76,768 | 37,962 | — | (82,146) | — | 32,584 |
| Total | <u>\$ 2,202,021</u> | <u>\$ 92,929</u> | <u>\$ (2,695)</u> | <u>\$ 6,848</u> | <u>\$ (60)</u> | <u>\$ 2,299,043</u> |
| | Balance as of January 1, 2025 | Depreciation | Disposals | Reclassification | Effect of exchange differences | Balance as of June 30, 2025 |
| Accumulated Depreciation and Impairment: | | | | | | |
| Buildings and facilities | \$ 241,788 | \$ 11,612 | \$ — | \$ — | \$ — | \$ 253,400 |
| Machinery and equipment | 368,464 | 23,631 | — | — | (59) | 392,036 |
| Transportation equipment | 3,989 | 258 | — | — | — | 4,247 |
| Office equipment | 102,459 | 6,191 | (1,595) | — | — | 107,055 |
| Leasehold improvements | 36,964 | 8,252 | — | — | — | 45,216 |
| Miscellaneous equipment | 32,437 | 2,254 | (1,099) | — | — | 33,592 |
| Total | <u>\$ 786,101</u> | <u>\$ 52,198</u> | <u>\$ (2,694)</u> | <u>\$ —</u> | <u>\$ (59)</u> | <u>\$ 835,546</u> |

| | Balance as of January 1, 2024 | Additions - individually acquired | Disposals | Reclassification | Effect of exchange differences | Balance as of June 30, 2024 |
|---|----------------------------------|---|-------------------|------------------|--------------------------------------|--------------------------------|
| Cost: | | | | | | |
| Land, buildings, and facilities | \$ 997,954 | \$ 968 | \$ — | \$ 4,166 | \$ — | \$ 1,003,088 |
| Machinery and equipment | 675,454 | 8,072 | (147) | 30,477 | 18 | 713,874 |
| Transportation equipment | 6,206 | 571 | (1,448) | — | — | 5,329 |
| Office equipment | 137,524 | 3,514 | (57) | 390 | — | 141,371 |
| Leasehold improvements | 129,659 | 6,462 | — | 762 | — | 136,883 |
| Miscellaneous equipment | 53,348 | 5,913 | (304) | — | — | 58,957 |
| Construction in progress and equipment under installation | 46,264 | 17,905 | — | (35,795) | — | 28,374 |
| Total | \$ 2,046,409 | \$ 43,405 | \$ (1,956) | \$ — | \$ 18 | \$ 2,087,876 |
| | Balance as of January 1, 2024 | Depreciation | Disposals | Reclassification | Effect of exchange differences | Balance as of June 30, 2024 |
| Accumulated Depreciation and Impairment: | | | | | | |
| Buildings and facilities | \$ 219,630 | \$ 10,942 | \$ — | \$ — | \$ — | \$ 230,572 |
| Machinery and equipment | 334,973 | 21,504 | (143) | — | 16 | 356,350 |
| Transportation equipment | 4,898 | 211 | (1,387) | — | — | 3,722 |
| Office equipment | 91,441 | 5,762 | (52) | — | — | 97,151 |
| Leasehold improvements | 21,853 | 6,663 | — | — | — | 28,516 |
| Miscellaneous equipment | 28,842 | 1,811 | (292) | — | — | 30,361 |
| Total | \$ 701,637 | \$ 46,893 | \$ (1,874) | \$ — | \$ 16 | \$ 746,672 |

C. The interest capitalization amount for the merged company for the second quarter of 2025 and 2024 is NT\$0 thousand.

D. Please refer to Note 8 for the amount of property, plant, and equipment set by the consolidated company as collateral for a loan.

(8) Lease arrangements

A. Right-of-use assets

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|------------------|----------------------|------------------|
| The carrying amount of right-of-use assets | | | |
| Buildings and facilities | \$ 12,349 | \$ 15,779 | \$ 19,891 |
| Transportation equipment | 813 | 1,301 | 1,789 |
| Total | \$ 13,162 | \$ 17,080 | \$ 21,680 |

| | Six Months Ended June 30 | |
|-------------------------------------|--------------------------|-----------------|
| | 2025 | 2024 |
| Additions to right-of-use assets | \$ 709 | \$ — |
| Depreciation of right-of-use assets | | |
| Buildings and facilities | \$ 4,138 | \$ 4,112 |
| Office equipment | — | — |
| Transportation equipment | 488 | 488 |
| Total | <u>\$ 4,626</u> | <u>\$ 4,600</u> |

B. Lease liabilities

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------|-----------------|-------------------|------------------|
| Current | <u>\$ 9,445</u> | <u>\$ 9,214</u> | <u>\$ 9,491</u> |
| Non-current | <u>\$ 3,913</u> | <u>\$ 8,173</u> | <u>\$ 12,506</u> |

The ranges of discount rates for lease liabilities are listed as follows:

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--------------------------|---------------|-------------------|---------------|
| Buildings and facilities | 1.350% | 1.350% | 1.350% |
| Transportation equipment | 2.072% | 2.072% | 2.072% |

C. Other lease information:

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|----------------------------|---------------|--------------------------|-------------------|
| | 2025 | 2024 | 2025 | 2024 |
| Short-term lease and low-value asset expenses | <u>\$ 344</u> | <u>\$ 717</u> | <u>\$ 737</u> | <u>\$ 1,439</u> |
| Total cash outflow for leases | | | <u>\$ (4,738)</u> | <u>\$ (4,572)</u> |

The consolidated company chooses to exempt the leases applicable to leases such as housing eligible for short-term leases and certain office equipment, such as low-value assets and does not recognize the relevant right of use assets and lease liabilities for such tenancies.

D. Operating leasing commitment - the consolidated company as a lessor

The consolidated company leases offices and factories by means of operating lease. The future minimum lease payments under non-cancellable operating leases as of June 30, 2025, and 2024 were listed as follows:

| Items | June 30, 2025 | June 30, 2024 |
|--|------------------|------------------|
| Less than 1 year | \$ 11,870 | \$ 30,496 |
| More than 1 year but less than 5 years | 7,358 | 55,575 |
| Total | <u>\$ 19,228</u> | <u>\$ 86,071</u> |

(9) Investment property

A. The carrying amounts of the consolidated company's investment property are listed as follows:

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--------------------------|-------------------|-------------------|-------------------|
| Land | \$ 557,177 | \$ 557,177 | \$ 557,177 |
| Buildings and facilities | 103,052 | 105,070 | 107,099 |
| Total | <u>\$ 660,229</u> | <u>\$ 662,247</u> | <u>\$ 664,276</u> |

B. Changes in costs, depreciation, and impairment loss on the Group's investment property are detailed as follows:

| Cost | Land | Buildings and facilities | Total |
|---|-------------------|--------------------------|-------------------|
| Balance as of January 1, 2025 | \$ 557,177 | \$ 151,867 | \$ 709,044 |
| Additions | — | — | — |
| Balance as of June 30, 2025 | <u>\$ 557,177</u> | <u>\$ 151,867</u> | <u>\$ 709,044</u> |
| Accumulated Depreciation and Impairment | | | |
| Balance as of January 1, 2025 | \$ — | \$ 46,797 | \$ 46,797 |
| Depreciation | — | 2,018 | 2,018 |
| Balance as of June 30, 2025 | <u>\$ —</u> | <u>\$ 48,815</u> | <u>\$ 48,815</u> |

| Cost | Land | Buildings and facilities | Total |
|---|------------|--------------------------|------------|
| Balance as of January 1, 2024 | \$ 557,177 | \$ 151,867 | \$ 709,044 |
| Additions | — | — | — |
| Balance as of June 30, 2024 | \$ 557,177 | \$ 151,867 | \$ 709,044 |
| Accumulated Depreciation and Impairment | | | |
| Balance as of January 1, 2024 | \$ — | \$ 42,485 | \$ 42,485 |
| Depreciation | — | 2,283 | 2,283 |
| Balance as of June 30, 2024 | \$ — | \$ 44,768 | \$ 44,768 |

- C. As of June 30, 2025 and 2024, the fair values of the investment properties held by the consolidated company were NT\$859,365 thousand and NT\$822,219 thousand, respectively. The merged company's investment real estate is to appoint an independent external appraisal expert to evaluate the fair value. The fair value is estimated based on market evidence of similar real estate transaction prices.
- D. The rental income generated from investment properties for the periods April 1 to June 30, 2025 and 2024 and from January 1 to June 30, 2025 and 2024 were NT\$4,487 thousand, NT\$8,201 thousand, NT\$10,270 thousand and NT\$16,388 thousand, respectively. There were no direct operating expenses incurred from January 1 to June 30, 2025 and 2024.
- E. For investment property pledged by the Group, please refer to Note 8.

(10) Intangible assets

- A. The carrying amounts of the Group's intangible assets are listed as follows:

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|------------------------|---------------|-------------------|---------------|
| Computer software | \$ 5,223 | \$ 4,956 | \$ 4,890 |
| Goodwill | 398,359 | 398,359 | 398,359 |
| Proprietary technology | 156,347 | 166,770 | 177,193 |
| Trademark rights | 197,121 | 210,262 | 223,404 |
| Total | \$ 757,050 | \$ 780,347 | \$ 803,846 |

B. The consolidated company's changes in costs, amortizations and impairment losses of the intangible assets are detailed as follows:

| | Balance as of January 1, 2025 | Additions - individually acquired | Disposals | Balance as of June 30, 2025 |
|------------------------|----------------------------------|---|-------------|--------------------------------|
| Cost: | | | | |
| Computer software | \$ 22,629 | \$ 1,876 | \$ — | \$ 24,505 |
| Goodwill | 398,359 | — | — | 398,359 |
| Proprietary technology | 208,462 | — | — | 208,462 |
| Trademark rights | 262,828 | — | — | 262,828 |
| Total | <u>\$ 892,278</u> | <u>\$ 1,876</u> | <u>\$ —</u> | <u>\$ 894,154</u> |

| | Balance as of January 1, 2025 | Amortization | Disposals | Balance as of June 30, 2025 |
|---|----------------------------------|------------------|-------------|--------------------------------|
| Accumulated amortization and impairment: | | | | |
| Computer software | \$ 17,673 | \$ 1,609 | \$ — | \$ 19,282 |
| Proprietary technology | 41,692 | 10,423 | — | 52,115 |
| Trademark rights | 52,566 | 13,141 | — | 65,707 |
| Total | <u>\$ 111,931</u> | <u>\$ 25,173</u> | <u>\$ —</u> | <u>\$ 137,104</u> |

| | Balance as of January 1, 2024 | Additions - individually acquired | Disposals | Balance as of June 30, 2024 |
|------------------------|----------------------------------|---|-------------|--------------------------------|
| Cost: | | | | |
| Computer software | \$ 18,309 | \$ 2,411 | \$ — | \$ 20,720 |
| Goodwill | 398,359 | — | — | 398,359 |
| Proprietary technology | 208,462 | — | — | 208,462 |
| Trademark rights | 262,828 | — | — | 262,828 |
| Total | <u>\$ 887,958</u> | <u>\$ 2,411</u> | <u>\$ —</u> | <u>\$ 890,369</u> |

| | Balance as of January 1, 2024 | Amortization | Disposals | Balance as of June 30, 2024 |
|---|----------------------------------|------------------|-------------|--------------------------------|
| Accumulated amortization and impairment: | | | | |
| Computer software | \$ 14,990 | \$ 840 | \$ — | \$ 15,830 |
| Proprietary technology | 20,846 | 10,423 | — | 31,269 |
| Trademark rights | 26,283 | 13,141 | — | 39,424 |
| Total | <u>\$ 62,119</u> | <u>\$ 24,404</u> | <u>\$ —</u> | <u>\$ 86,523</u> |

C. No impairment losses on goodwill were recognized for the six months ended June 30, 2025 and 2024 in the consolidated company.

- D. Amortization expense that should be recognized in the Group's intangible assets has been included in operating costs and operating expenses provided in the consolidated statements of profit and loss.

(11) Loans

A. Short-term loans

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------------------|--------------------|----------------------|--------------------|
| Bank loans | | | |
| Unsecured loans | \$ 300,000 | \$ 500,000 | \$ — |
| Secured loans | 400,000 | 762,000 | 375,000 |
| Total | <u>\$ 700,000</u> | <u>\$ 1,262,000</u> | <u>\$ 375,000</u> |
| Range of interest rates | <u>2.18%~2.53%</u> | <u>2.10%~2.60%</u> | <u>2.24%~2.40%</u> |

B. Long-term loans

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-----------------------|-------------------|----------------------|---------------------|
| Bank loans | | | |
| Secured loans | \$ 645,602 | \$ 1,061,121 | \$ 1,558,578 |
| Less: current portion | (36,723) | (641,123) | (234,854) |
| Total | <u>\$ 608,879</u> | <u>\$ 419,998</u> | <u>\$ 1,323,724</u> |

- C. For assets pledged by the Group as collateral for long-term borrowings, please refer to Note 8.

- D. For details of the consolidated company's interest rate, foreign currency, and liquidity risk, please refer to Note 6(26).

(12) Other payables

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|-------------------|----------------------|---------------------|
| Accrued expenses: | | | |
| Salaries, bonuses and employee social insurance | \$ 69,218 | \$ 80,381 | \$ 58,599 |
| Commission expense | 3,315 | 3,497 | 5,113 |
| Other accrued expenses | 52,199 | 49,796 | 45,395 |
| Subtotal | <u>124,732</u> | <u>133,674</u> | <u>109,107</u> |
| Business tax payable | 3,339 | 7,578 | 4,406 |
| Equipment payables | 8,984 | 14,715 | 10,642 |
| Dividends payable | 543,732 | — | 1,120,251 |
| Total | <u>\$ 680,787</u> | <u>\$ 155,967</u> | <u>\$ 1,244,406</u> |

(13) Bonds payable

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--------------------------------------|-------------------|----------------------|---------------------|
| Domestic unsecured convertible bonds | \$ 1,944,300 | \$ 1,944,300 | \$ 2,239,100 |
| Domestic secured convertible bonds | 2,624,900 | 2,624,900 | 2,624,900 |
| Less: Discounts on bonds payable | (306,062) | (379,579) | (502,603) |
| Less: current portion | (3,672,049) | (1,954,704) | — |
| Total | <u>\$ 591,089</u> | <u>\$ 2,234,917</u> | <u>\$ 4,361,397</u> |

Changes from January 1 to June 30, 2025 and 2024:

| Items | June 30, 2025 | June 30, 2024 |
|--|-------------------|---------------------|
| Liability component on January 1 | \$ 4,189,621 | \$ 4,350,826 |
| Interest calculated using the effective interest rate | 73,517 | 78,187 |
| Less: Issuance of ordinary shares of convertible bonds | — | (67,616) |
| Less: current portion | (3,672,049) | — |
| Liability component on June 30 | <u>\$ 591,089</u> | <u>\$ 4,361,397</u> |

A. Fourth Domestic Secured Convertible Bonds

On September 7, 2020, the Company issued 5,000 units of New Taiwan Dollar-denominated zero-coupon secured convertible bonds totaling NT\$500,000 thousand.

Each unit bondholder has the right to convert their bonds into ordinary shares of the Company at a rate of NT\$91 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. On the third anniversary of the issuance of the convertible bonds, bondholders can request the Company to redeem their bonds in cash at 100.75% of the face value plus accrued interest, resulting in an effective yield 0.25%.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 1.0452%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

| | | |
|--|----|---------|
| The present value of the compound interest on convertible corporate bonds | \$ | 474,668 |
| Embedded derivative instrument - the right of redemption and put-back | | 1,530 |
| Equity component at issuance | | 22,491 |
| Issue price of convertible bonds (net of issuance costs of NT\$1,311 thousand) | \$ | 498,689 |

B. Fifth Domestic Unsecured Convertible Bonds

On September 8, 2020, the Company issued 15,000 units of New Taiwan Dollar-denominated zero-coupon unsecured convertible bonds totaling NT\$1,500,000 thousand.

In compliance with Article 7 of the Conversion Bond Act, effective from the issuance date of the sixth domestically secured convertible bond issuance (i.e., April 6, 2023), the Company set up an equivalent class of bonds or collateral rights in the same order as the secured convertible bond.

Holders of each unit of the convertible bonds are entitled to convert them into ordinary shares of the Company at NT\$90 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. Holders of the convertible bonds may request the Company to redeem the convertible bonds they held in cash at the par value of the convertible bonds plus an interest compensation equivalent to 102.27% (or an effective yield of 0.75%) of the par value of the convertible bonds at the end of three years from the issuance of the convertible bonds.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 3.0877%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

| | | |
|--|----|------------------|
| The present value of the compound interest on convertible corporate bonds | \$ | 1,288,418 |
| Embedded derivative instrument - the right of redemption and put-back | | 38,760 |
| Equity component at issuance | | <u>168,979</u> |
| Issue price of convertible bonds (net of issuance costs of NT\$3,843 thousand) | \$ | <u>1,496,157</u> |

C. Sixth Domestic Secured Convertible Bonds

On April 26, 2023, the Company issued 7,000 units of secured convertible bonds with a coupon rate of 0% and a total principal amount of NT\$700,000 thousand in Taiwan. The bonds were publicly underwritten by auction at 110.08% of face value, and the actual amount of bonds issued was NT\$770,583 thousand.

Each unit bondholder has the option to convert their bonds into ordinary shares of the company at a rate of NT\$48 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 2.647%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

| | | |
|--|----|----------------|
| The present value of the compound interest on convertible corporate bonds | \$ | 614,362 |
| Embedded derivative instrument - the right of put-back | | (5,488) |
| Equity component at issuance | | <u>160,623</u> |
| Issue price of convertible bonds (net of issuance costs of NT\$1,086 thousand) | \$ | <u>769,497</u> |

D. Seventh Domestic Unsecured Convertible Bonds

On April 27, 2023, the Company issued 25,000 units of unsecured convertible bonds denominated in New Taiwan dollars with a coupon rate of 0% and a total principal amount of NT\$2,500,000 thousand in Taiwan.

Holders of each unit of the convertible bonds are entitled to convert them into ordinary shares of the Company at NT\$49 per share. The conversion period for the convertible bonds is three months from the date when the convertible bonds were issued to the maturity date. Holders of the convertible bonds may request the Company to redeem the convertible bonds they held in cash at the par value of the convertible bonds plus an interest compensation equivalent to 103.03% (or an effective yield of 1%) of the par value of the convertible bonds at the end of three years from the issuance of the convertible bonds.

The convertible bonds consist of both debt and equity components, with the equity component being represented as capital surplus - stock options under equity items. The original recognized effective interest rate for the debt component is 5.03917%.

During the issuance of the convertible bonds, the conversion option of the bonds was separated from liabilities. Information on the recognition of the convertible bonds in equity and liabilities is provided as follows:

| | | |
|--|----|------------------|
| The present value of the compound interest on convertible corporate bonds | \$ | 1,955,165 |
| Embedded derivative instrument - the right of redemption and put-back | | 41,075 |
| Equity component at issuance | | <u>499,918</u> |
| Issue price of convertible bonds (net of issuance costs of NT\$3,842 thousand) | \$ | <u>2,496,158</u> |

(14) Employee benefits

A. Defined contribution plan

Since subsidiaries of the Company, including Center Biotherapeutics Inc., Centerlab Investment Holding Limited, Center Laboratories Limited, Center Venture Holding I Limited, Center Venture Holding II Limited, Center Venture Holding III Limited, Bioflag International Corporation, Bioflag Co., Ltd., and Genlac Biotech Inc. do not hire full-time employees, their investing activities are carried out by the Company and management consulting firms. Hence, there is no relevant pension system in these subsidiaries.

The pension system of the Labor Pensions Ordinance applies to the Company and Glac Biotech Co., Ltd. is a definitive allocation scheme, which has been allocated to the individual pension account of the Labor Insurance Bureau based on 6 percent of the employee's monthly salary since July 1, 2005.

The retirement pensions of the remaining subsidiaries are determined by the definite allocation system, and various social security funds such as pensions and medical care are paid to the local government every month according to laws and regulations.

The total recognized expenses for defined contribution plans in the income statement for the periods from April 1 to June 30, 2025 and 2024 and from January 1 to June 30, 2025 and 2024 were NT\$4,595 thousand, NT\$4,885 thousand, NT\$9,087 thousand and NT\$9,345 thousand, respectively.

B. Defined benefits plan

Where the Company and Glac Biotech Co., Ltd. adopt the government-managed defined benefit plan as their pension system applicable under the Labor Standards Act, each employee whose has served the company for up to 15 years, shall be given two bases for each full year of service rendered, while each employee who has served the Company over 15 years shall be given one base for each full year of service rendered. An employee shall not receive more than 45 bases in total. Employees' pension payments are based on the number of years of service and the average salary of the six months before the approved retirement date (the "basis"). The Company contributes 2% of salaries and wages to a monthly pension fund, which is deposited in the Bank of Taiwan in the name of the Labor Pension Fund Supervisory Committee.

Before the end of each year, if the balance in the account is inadequate to pay pensions to workers retiring in the same year, the difference has to be made up in a one-off contribution before the end of March the following year. This special account is managed by the Labor Fund Utilization Bureau of the Ministry of Labor, and the Company has no right to influence the investment management strategy.

According to the aforementioned regulations, the retirement benefit cost (income) recognized as expenses in the statement of comprehensive income for the Company for the periods from April 1 to June 30, 2025 and 2024 and from January 1 to June 30, 2025 and 2024 were NT\$(36) thousand, NT\$(5) thousand, NT\$(71) thousand and NT\$(9) thousand, respectively.

(15) Equity

A. Ordinary shares

As of June 30, 2025, and 2024, the issued capital was NT\$10,000,000 thousand and the par value of each share is NT\$10, all of which are 1,000,000 thousand shares. As of June 30, 2025 and 2024, the paid-in capital amounted to NT\$7,249,768 thousand and NT\$7,181,528 thousand, respectively, divided into 724,977 thousand shares of common stock and 718,152 thousand shares of common stock.

Based on the resolution passed by the shareholders' meeting in June 2015, the Company conducted a private placement of ordinary shares by issuing 15,000 thousand ordinary shares at a premium of \$62.1 per share in November 2015, and raised \$931,500 thousand in capital, where the record date for capital increase was November 26, 2015. In June 2016, the Company issued 5,000 thousand ordinary shares at a premium of \$62.1 per share and raised \$310,500 thousand in capital, with the record date for the capital increase being June 22, 2016. The rights and obligations of the privately-placed ordinary shares are the same as those of other ordinary shares, except for the restrictions on transferability under the Securities and Exchange Act and the requirement that the shares must be held for three years from the date of delivery and must be reissued after the issuance of the shares to apply for over-the-counter quotations.

B. Capital surplus

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--|---------------------|----------------------|---------------------|
| Issued at premium | \$ 3,510,412 | \$ 4,054,144 | \$ 3,813,462 |
| Changes in net equity of associates and joint ventures accounted for using the equity method | 641,341 | 665,876 | 1,091,577 |
| Difference between consideration and carrying amount of subsidiaries acquired or disposed | 21 | — | — |
| Stock options | 729,420 | 725,873 | 784,021 |
| Treasury shares | 88,455 | 88,455 | 81,437 |
| Others | 1,656 | 1,609 | 1,609 |
| Total | <u>\$ 4,971,305</u> | <u>\$ 5,535,957</u> | <u>\$ 5,772,106</u> |

(a) Increase in ordinary share premium is due to capital increase and convertible bond premium.

- (b) Changes in the net equity of associates and joint ventures accounted for using the equity method are due to difference in net equity arising from changes in the shareholders' equity of investees and changes in the percentage of ownership.
- (c) The difference between the acquisition or disposal of the equity price of a subsidiary company and the book value is the acquisition or sale of the equity of the subsidiary. Since it has not lost control, it is regarded as an equity transaction and transferred to the capital surplus.
- (d) According to the Company Act, capital surplus may not be used for any purpose other than to offset a deficit. However, capital surplus from the issue of stock in excess of par value (including the excess of par value of ordinary shares issued, capital surplus from stock issued in connection with a merger, and treasury stock transactions) and the proceeds from the receipt of gifts may be transferred to capital, and such transfer is limited to a certain percentage of the paid-in capital each year. Capital surplus from long-term investments may not be used for any purpose.

In addition, under the Company Law amended in January 2012, if a company has no losses, the capital surplus from the issue of stock in excess of par value and the capital surplus from gifts may be distributed in cash in proportion to the shareholders' original shareholdings.

C. Retained earnings

Based on the Articles of Association, the annual earnings of the Company shall be first appropriated to pay taxes and offset accumulated losses before allocating 10% of the remaining earning to the legal capital reserve (not applicable where accumulated legal capital reserve has reached the amount required by law and regulations) and a special capital reserve in accordance to the Company's operating needs and pursuant to the applicable law and regulations. Any retained earnings available for distribution together with accumulated undistributed retained earnings may be proposed by the Board of Directors to appropriate and be resolved at the Annual General Meeting.

According to the Company's Articles of Incorporation, a dividend policy aims to establish a comprehensive financial structure and ensure investors' interests; hence, the Company adopts a dividend equalization policy, where earnings to be appropriated shall be no less than 50% of the unappropriated earnings for the current year, and at least 10% of dividends to be distributed in the current year shall be distributed as cash dividends. If the dividend distributed in that year is less than NT\$3, all of it shall be distributed as stock dividends.

(a) Legal reserve

The legal reserve should be allocated until it reaches the total amount of the Company's paid-in capital. It can also be used to offset losses. According to the amended provisions of the Company Law announced on January 4, 2012, any excess amount of the legal reserve exceeding 25% of the total paid-in capital can be allocated to increase the capital or distributed in cash.

(b) Special reserve

The Company appropriates or reserves special reserve according to the Company's needs, which is subject to the resolution of the shareholders meeting, and in accordance with the Letter No. 1010012865, Letter No. 1010047490 and Letter No. 1030006415 issued by the FSC and the directive titled "Questions and Answers for Special Reserves Appropriated Following Adoption of IFRSs."

D. Appropriation of earnings

The Company resolved at the shareholders' meeting on June 26, 2025, to approve the distribution of earnings and the allocation of cash from the capital reserve as follows.

| | 2024 | |
|-------------------------------------|---------|----------------------------|
| | Amount | Dividends per share (NT\$) |
| Stock dividends | 362,488 | 0.5 |
| Cash dividends from capital surplus | 543,732 | 0.75 |

The cash dividends from capital surplus, which were proposed and approved in the shareholders' meetings on June 25, 2024 was as follows:

| | 2023 | |
|-------------------------------------|-----------|----------------------------|
| | Amount | Dividends per share (NT\$) |
| Cash dividends from capital surplus | 1,037,159 | 1.50 |

For the appropriation of earnings proposed by the Board of Directors and approved by the shareholders' meeting at the Company, please visit the Market Observation Post System.

E. Other equity

Changes in other equity items for the six months ended June 30, 2025 and 2024 are as follows:

| | Unrealized gain (loss) on financial assets at fair value through other comprehensive income | Exchange differences arising on translation of foreign operations | Total |
|--|--|--|-------------|
| Balance as of January 1, 2025 | \$ 19,603 | \$ (739) | \$ 18,864 |
| Exchange differences arising on translation of foreign operations | — | (103,195) | (103,195) |
| Share of other comprehensive income of associates and joint ventures accounted for using the equity method | — | (13,583) | (13,583) |
| Balance as of June 30, 2025 | \$ 19,603 | \$ (117,517) | \$ (97,914) |

| | Unrealized gain (loss) on financial assets at fair value through other comprehensive income | Exchange differences arising on translation of foreign operations | Total |
|--|--|--|-----------|
| Balance as of January 1, 2024 | \$ 74,820 | \$ (50,396) | \$ 24,424 |
| Exchange differences arising on translation of foreign operations | — | 36,260 | 36,260 |
| Share of other comprehensive income of associates and joint ventures accounted for using the equity method | — | 9,632 | 9,632 |
| Balance as of June 30, 2024 | \$ 74,820 | \$ (4,504) | \$ 70,316 |

F. Treasury shares

(a) Reasons and quantities of treasury stock for the second quarter of 2025 and 2024:

| Reason for Reacquisition | Second Quarter of 2025 | | | Unit: thousand shares |
|--|--|-------------------------------|-------------------------------|---------------------------------------|
| | Number of Shares, Beginning of Period | Increase in current period | Decrease in current period | Number of Shares, End of Period |
| Shares of the Company held by subsidiaries | 4,553 | — | — | 4,553 |
| Transfer of Shares to Employees | — | 9,909 | — | 9,909 |
| Total | 4,553 | 9,909 | — | 14,462 |

| Reason for Reacquisition | Second Quarter of 2024 | | | Unit: thousand shares |
|--|---------------------------------------|----------------------------|----------------------------|---------------------------------|
| | Number of Shares, Beginning of Period | Increase in current period | Decrease in current period | Number of Shares, End of Period |
| Shares of the Company held by subsidiaries | 5,358 | — | 765 | 4,593 |

As of June 30, 2025 and 2024, the market value of the treasury shares held by the subsidiaries of the Company was NT\$173,912 thousand and NT\$249,842 thousand, respectively.

- (b) According to the Securities and Exchange Act, the number of shares outstanding repurchased by the Company shall not exceed 10% of the number of issued shares, and the total amount repurchased shall not exceed the sum of the Company's retained earnings, share premium, and realized capital surplus.
- (c) According to the Securities and Exchange Act, treasury shares held by the Company shall not be pledged, and may not hold any shareholder rights before their transfer. The subsidiaries holding the aforementioned treasury shares are bestowed shareholders' rights, except the rights to participate in any capital increase by cash and to vote.

G. Non-controlling interests

| Items | June 30, 2025 | June 30, 2024 |
|---|---------------|---------------|
| Beginning balance | \$ 6 | \$ 459,349 |
| Net income | — | 275 |
| Increase (decrease) in non-controlling interests in subsidiary acquisitions | — | (459,618) |
| Ending balance | \$ 6 | \$ 6 |

(16) Share-based payment arrangements

- A. As of June 30, 2025, the Company's equity-based compensation agreement is as follows:

| Type of Agreement | Grant Date | Number of Shares Granted (thousand shares) | Contractual Period | Vesting Conditions |
|----------------------------|------------|--|--------------------|--------------------|
| Employee Stock Option Plan | 2024.11.21 | 3,000 | 4 years | Note 1 |

Note 1: After an employee has been granted stock options and two years have elapsed, they may exercise their stock options according to the schedule and proportion specified in the plan, provided they are still employed and have achieved the operational performance targets.

B. Information on these employee stock warrants is provided as follows:

| Employee Stock Warrants | Six Months Ended June 30, 2025 | |
|---|--------------------------------|--|
| | Number of Units | Weighted Average Exercise Price (NT\$) |
| Stock warrants outstanding Beginning Balance | 3,000 | \$ 50.50 |
| Forfeitures waived during the current period | (66) | 50.50 |
| Stock warrants outstanding at the end of the period | 2,934 | 50.50 |
| Stock warrants exercisable at the end of the period | — | |
| The weighted average of stock warrants granted | — | |

C. As of June 30, 2025, the following information pertains to the employee stock options currently in circulation:

| Range of Exercise Prices (NT\$) | Current External Units | Weighted Average Expected Remaining Duration (Years) | Weighted Average Exercise Price (NT\$) | Implementing Unit | Weighted Average Exercise Price of Exercisable Stock Warrants |
|---------------------------------|------------------------|--|--|-------------------|---|
| 50.5 | 2,934 | 3.39 | 50.5 | — | — |

D. The employee stock option above uses Black-Scholes option evaluation mode to estimate the fair value of the subscription option, and the information relating thereto is as follows:

| Type of Agreement | Grant Date | Share Price | Exercise Price | Expected Volatility | Expected Lifetime | Expected Dividends | Risk-free Rate | Weighted Average Fair Value per Share (NT\$) |
|----------------------------|------------|-------------|----------------|---------------------|-------------------|--------------------|----------------|--|
| Employee Stock Option Plan | 2024.11.21 | 50.5 | 50.5 | 29.51% | 4 years | 0.00% | 1.41%~1.44% | 10.01 |

E. The Company recognizes the compensation cost of NT\$3,547 thousand for the stock-based payment in the second quarter of 2025.

(17) Transactions with Non-controlling Interests

The Company formerly held 47.33% of the shares of Bioflag International Corporation through its subsidiary, Centerlab Investment Holding Limited. In May 2024, the Company acquired 52.67% of the shares of Bioflag International Corporation through the issuance of new shares. After the share exchange, Bioflag International Corporation became a wholly-owned subsidiary of the Company.

| Items | June 30, 2024 |
|---|---------------|
| Acquired book value of non-controlling interests | \$ 459,618 |
| Payment of share consideration for non-controlling interests | (1,171,346) |
| Difference between acquisition price and carrying value of equity in subsidiaries | \$ (711,728) |
| Equity transaction balance adjustment account | |
| Capital surplus | \$ (449,327) |
| Accumulated Profit/Loss | \$ (262,401) |

(18) Revenue from contracts with customers

A. Details of revenue

| Three Months Ended June 30, 2025 | | | |
|----------------------------------|-------------------------|----------------|----------------|
| | Pharmaceutical Division | Glac Segment | Total |
| <u>Major Regional Markets</u> | | | |
| Taiwan | 230,365 | 62,526 | 292,891 |
| China | — | 80,956 | 80,956 |
| Others | — | 4,864 | 4,864 |
| | <u>230,365</u> | <u>148,346</u> | <u>378,711</u> |
| <u>Major Products / Services</u> | | | |
| Western pharmaceuticals | 230,365 | — | 230,365 |
| Probiotics | — | 148,346 | 148,346 |
| Total | <u>230,365</u> | <u>148,346</u> | <u>378,711</u> |
| Six Months Ended June 30, 2025 | | | |
| | Pharmaceutical Division | Glac Segment | Total |
| <u>Major Regional Markets</u> | | | |
| Taiwan | 475,489 | 114,364 | 589,853 |
| China | — | 155,004 | 155,004 |
| Others | — | 12,713 | 12,713 |
| | <u>475,489</u> | <u>282,081</u> | <u>757,570</u> |
| <u>Major Products / Services</u> | | | |
| Western pharmaceuticals | 475,489 | — | 475,489 |
| Probiotics | — | 282,081 | 282,081 |
| Total | <u>475,489</u> | <u>282,081</u> | <u>757,570</u> |

| Three Months Ended June 30, 2024 | | | |
|----------------------------------|-------------------------|----------------|----------------|
| | Pharmaceutical Division | Glac Segment | Total |
| <u>Major Regional Markets</u> | | | |
| Taiwan | 241,051 | 57,777 | 298,828 |
| China | — | 107,193 | 107,193 |
| Others | — | 7,398 | 7,398 |
| | <u>241,051</u> | <u>172,368</u> | <u>413,419</u> |
| <u>Major Products / Services</u> | | | |
| Western pharmaceuticals | 241,051 | — | 241,051 |
| Probiotics | — | 172,368 | 172,368 |
| Total | <u>241,051</u> | <u>172,368</u> | <u>413,419</u> |
| Six Months Ended June 30, 2024 | | | |
| | Pharmaceutical Division | Glac Segment | Total |
| <u>Major Regional Markets</u> | | | |
| Taiwan | 488,285 | 99,916 | 588,201 |
| China | — | 171,787 | 171,787 |
| Others | — | 16,841 | 16,841 |
| | <u>488,285</u> | <u>288,544</u> | <u>776,829</u> |
| <u>Major Products / Services</u> | | | |
| Western pharmaceuticals | 488,285 | — | 488,285 |
| Probiotics | — | 288,544 | 288,544 |
| Total | <u>488,285</u> | <u>288,544</u> | <u>776,829</u> |

B. Contract assets and liabilities

Below are the contractual assets and contractual liabilities related to the Customer Contract Revenues confirmed by the Company:

| | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|-------------------|-------------------|-------------------|
| Accounts receivable (including related parties) | \$ 202,756 | \$ 180,354 | \$ 188,037 |
| Less: Loss allowance | (1,272) | (1,775) | (1,603) |
| | <u>\$ 201,484</u> | <u>\$ 178,579</u> | <u>\$ 186,434</u> |
| Contract liabilities - current | | | |
| Product Sales | \$ 159,938 | \$ 157,323 | \$ 122,701 |
| Provision of Services | — | 1,923 | — |
| | <u>\$ 159,938</u> | <u>\$ 159,246</u> | <u>\$ 122,701</u> |
| Contract liabilities - non-current | | | |
| Provision of Services | <u>\$ 8,521</u> | <u>\$ 4,841</u> | <u>\$ —</u> |

Contract liabilities are mainly due to advance receipts from commodity sales contracts, which will be transferred to revenue when the products are delivered to customers.

- (19) Employee benefits, depreciation, and amortization expenses are summarized by function as follows:

| Three Months Ended June 30 | | | | | | |
|----------------------------|-----------------|--------------------|---------|-----------------|--------------------|---------|
| Function Nature | 2025 | | | 2024 | | |
| | Operating Costs | Operating Expenses | Total | Operating Costs | Operating Expenses | Total |
| Employee benefits expense | | | | | | |
| Salaries | 41,044 | 67,802 | 108,846 | 38,218 | 62,893 | 101,111 |
| Labor and health insurance | 4,429 | 4,465 | 8,894 | 4,129 | 5,072 | 9,201 |
| Pension | 2,078 | 2,480 | 4,558 | 2,054 | 2,826 | 4,880 |
| Others | 3,328 | 2,056 | 5,384 | 4,147 | 1,624 | 5,771 |
| Subtotal | 50,879 | 76,803 | 127,682 | 48,548 | 72,415 | 120,963 |
| Depreciation | 24,887 | 5,340 | 30,227 | 20,892 | 6,340 | 27,232 |
| Amortization | 38 | 12,525 | 12,563 | 12 | 12,221 | 12,233 |

| Six Months Ended June 30 | | | | | | |
|----------------------------|-----------------|--------------------|---------|-----------------|--------------------|---------|
| Function Nature | 2025 | | | 2024 | | |
| | Operating Costs | Operating Expenses | Total | Operating Costs | Operating Expenses | Total |
| Employee benefits expense | | | | | | |
| Salaries | 82,671 | 120,710 | 203,381 | 71,263 | 113,963 | 185,226 |
| Labor and health insurance | 8,855 | 9,507 | 18,362 | 8,001 | 9,244 | 17,245 |
| Pension | 4,131 | 4,884 | 9,015 | 3,959 | 5,377 | 9,336 |
| Others | 6,196 | 3,617 | 9,813 | 7,656 | 3,226 | 10,882 |
| Subtotal | 101,853 | 138,718 | 240,571 | 90,879 | 131,810 | 222,689 |
| Depreciation | 48,253 | 10,590 | 58,843 | 40,922 | 12,854 | 53,776 |
| Amortization | 73 | 25,100 | 25,173 | 25 | 24,379 | 24,404 |

The Company allocates 0.1% to 10% and no more than 2% of its net profit before tax before deducting employee compensation and remuneration of directors and supervisors for the current year, as compensation and remuneration of directors and supervisors, respectively in accordance with its Articles of Incorporation.

As a result of the pre-tax loss for the six months ended June 30, 2025 and 2024, the Company was unable to provide employee compensation.

Changes in accounting estimates subsequent to the adoption of the annual financial statements are recognized as adjustments in the following year.

For information on the distribution of employee compensation and remuneration of directors and supervisors approved by the Company's Board of Directors, please visit the Market Observation Post System.

(20) Non-operating income and expenses

A. Finance costs

| Items | Three Months Ended June 30 | | Six Months Ended June 30 | |
|-------------------------------|----------------------------|-----------|--------------------------|------------|
| | 2025 | 2024 | 2025 | 2024 |
| Interest on bank loans | \$ 6,087 | \$ 13,629 | \$ 23,421 | \$ 22,317 |
| Interest on corporate bonds | 37,154 | 39,452 | 73,517 | 78,187 |
| Interest on lease liabilities | 51 | 82 | 107 | 170 |
| Others | 9 | 8 | 17 | 16 |
| Subtotal | 43,301 | 53,171 | 97,062 | 100,690 |
| Bank loan processing fee | 9,914 | 6,833 | 17,553 | 13,625 |
| Total | \$ 53,215 | \$ 60,004 | \$ 114,615 | \$ 114,315 |

(21) Components of other comprehensive income

| Three Months Ended June 30, 2025 | Amount | Reclassification Adjustment | Other Comprehensive Income | Income Tax Benefit (Expense) | Amount After Tax |
|--|--------------|--------------------------------|----------------------------------|------------------------------------|---------------------|
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | \$ (156,567) | \$ — | \$ (156,567) | \$ 31,314 | \$ (125,253) |
| Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | (16,997) | — | (16,997) | 1,005 | (15,992) |
| Other comprehensive income | \$ (173,564) | \$ — | \$ (173,564) | \$ 32,319 | \$ (141,245) |

| Three Months Ended June 30, 2024 | Amount | Reclassification Adjustment | Other Comprehensive Income | Income Tax Benefit (Expense) | Amount After Tax |
|--|-----------|--------------------------------|----------------------------------|------------------------------------|---------------------|
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | \$ 14,269 | \$ (3,454) | \$ 10,815 | \$ (2,185) | \$ 8,630 |
| Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | 4,721 | (887) | 3,834 | 2 | 3,836 |
| Other comprehensive income | \$ 18,990 | \$ (4,341) | \$ 14,649 | \$ (2,183) | \$ 12,466 |

| Six Months Ended June 30, 2025 | Amount | Reclassification Adjustment | Other Comprehensive Income | Income Tax Benefit (Expense) | Amount After Tax |
|--|---------------------|--------------------------------|----------------------------------|------------------------------------|---------------------|
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | \$ (128,994) | \$ — | \$ (128,994) | \$ 25,799 | \$ (103,195) |
| Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | (14,471) | — | (14,471) | 888 | (13,583) |
| Other comprehensive income | <u>\$ (143,465)</u> | <u>\$ —</u> | <u>\$ (143,465)</u> | <u>\$ 26,687</u> | <u>\$ (116,778)</u> |
| Six Months Ended June 30, 2024 | Amount | Reclassification Adjustment | Other Comprehensive Income | Income Tax Benefit (Expense) | Amount After Tax |
| Items that may be reclassified subsequently to profit or loss: | | | | | |
| Exchange differences arising on translation of foreign operations | \$ 48,806 | \$ (3,454) | \$ 45,352 | \$ (9,092) | \$ 36,260 |
| Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | 10,817 | (887) | 9,930 | (298) | 9,632 |
| Other comprehensive income | <u>\$ 59,623</u> | <u>\$ (4,341)</u> | <u>\$ 55,282</u> | <u>\$ (9,390)</u> | <u>\$ 45,892</u> |

(22) Income tax

A. Deferred tax assets (liabilities)

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|--------------------|----------------------|---------------------|
| Deferred tax assets | | | |
| Less: Allowance for inventory valuation losses | \$ 4,009 | \$ 3,967 | \$ 2,354 |
| Unrealized gain on financial assets | 17,681 | 20,733 | 2,618 |
| Investments accounted for using the equity method | 9,586 | 9,481 | 9,502 |
| Exchange differences arising on translation of foreign operations | (937) | (1,817) | (1,740) |
| Others | 691 | 141 | 677 |
| Subtotal | <u>\$ 31,030</u> | <u>\$ 32,505</u> | <u>\$ 13,411</u> |
| Deferred tax liabilities | | | |
| Less: Allowance for inventory valuation losses | \$ 1,309 | \$ 1,299 | \$ 1,085 |
| Bonds payable | (49,208) | (66,818) | (97,105) |
| Unrealized gain on financial assets | 164,856 | 60,093 | (94,990) |
| Land value increment tax | (11,718) | (11,718) | (11,718) |
| Investments accounted for using the equity method | (207,183) | (122,048) | 43,648 |
| Others | 1,033 | (6,041) | (6,969) |
| Exchange differences arising on translation of foreign operations | 22,299 | (3,508) | (1,311) |
| Subtotal | <u>\$ (78,612)</u> | <u>\$ (148,741)</u> | <u>\$ (167,360)</u> |

B. Details of the Company's income tax expense recognized in gain or loss are provided as follows:

| Items | Three Months Ended June 30 | | Six Months Ended June 30 | |
|--|----------------------------|--------------------|--------------------------|--------------------|
| | 2025 | 2024 | 2025 | 2024 |
| Current income tax expense | \$ 4,853 | \$ 130,959 | \$ 17,584 | \$ 160,201 |
| Deferred income tax expense (benefit) | (178,070) | (217,703) | (41,967) | (278,246) |
| Income basic tax | (69) | 9,964 | 415 | 9,964 |
| Repayment of income taxes in prior years | — | 413 | — | 413 |
| Underestimated (overestimated) income tax in prior years | (15,326) | (3,260) | (15,327) | (3,260) |
| Other (Withholding Tax) | — | 15,839 | — | 15,839 |
| Income tax expense (benefit) | <u>\$ (188,612)</u> | <u>\$ (63,788)</u> | <u>\$ (39,295)</u> | <u>\$ (95,089)</u> |

C. Income tax recognized in other comprehensive income

| Items | Three Months Ended June 30 | | Six Months Ended June 30 | |
|--|----------------------------|----------|--------------------------|----------|
| | 2025 | 2024 | 2025 | 2024 |
| Exchange differences arising on translation of foreign operations | \$ (31,314) | \$ 2,185 | \$ (25,799) | \$ 9,092 |
| Share of other comprehensive income or loss of associates and joint ventures accounted for using the equity method | (1,005) | (2) | (888) | 298 |
| Income tax expense (benefit) relating to items that may be reclassified to profit or loss | \$ (32,319) | \$ 2,183 | \$ (26,687) | \$ 9,390 |

D. The Company's income tax returns have been examined and approved by the tax authorities until the year ended December 31, 2022.

(23) Earnings per share

| | Three Months Ended June 30 | | | | | |
|------------------------------------|----------------------------|-------------------------|---------------------------|------------|-------------------------|---------------------------|
| | 2025 | | | 2024 | | |
| | Net income | Weighted average shares | Earnings per share (NT\$) | Net income | Weighted average shares | Earnings per share (NT\$) |
| Basic earnings per share | (726,536) | 722,477 | (1.01) | (72,469) | 699,623 | (0.10) |
| Dilutive potential ordinary shares | | | | | | |
| Employee compensation | — | — | | — | — | |
| Convertible bonds | — | — | | (Note) | — | |
| Diluted earnings per share | (726,536) | 722,477 | (1.01) | (72,469) | 699,623 | (0.10) |

| | Six Months Ended June 30 | | | | | |
|------------------------------------|--------------------------|-------------------------|---------------------------|------------|-------------------------|---------------------------|
| | 2025 | | | 2024 | | |
| | Net income | Weighted average shares | Earnings per share (NT\$) | Net income | Weighted average shares | Earnings per share (NT\$) |
| Basic earnings per share | (177,396) | 723,720 | (0.25) | (613,446) | 695,545 | (0.88) |
| Dilutive potential ordinary shares | | | | | | |
| Employee compensation | — | — | | — | — | |
| Convertible bonds | — | — | | (Note) | — | |
| Diluted earnings per share | (177,396) | 723,720 | (0.25) | (613,446) | 695,545 | (0.88) |

(Note) In calculating the surplus per diluted share, the inclusion of potential ordinary shares in the calculation of net gain (loss) per share will have a dilution effect and are not included in the calculation.

On June 26, 2025, the Company resolved at the shareholders' meeting to issue stock dividends without charge. If this stock dividend issuance occurs before the financial statements are approved for release, the retroactive adjustments to earnings per share are as follows:

| | Three Months Ended June 30 | | Six Months Ended June 30 | |
|-----------------------------------|----------------------------|-----------|--------------------------|-----------|
| | 2025 | 2024 | 2025 | 2024 |
| Basic earnings per share (NT\$) | \$ (0.96) | \$ (0.10) | \$ (0.23) | \$ (0.84) |
| Diluted earnings per share (NT\$) | \$ (0.96) | \$ (0.10) | \$ (0.23) | \$ (0.84) |

When the Company decides to distribute employee compensation in the form of stocks or cash, diluted earnings per share should be calculated based on the assumption that the employee compensation will be distributed in the form of stocks. The weighted average number of outstanding shares should include the potential ordinary shares that have a dilutive effect in order to calculate diluted earnings per share. Additionally, when calculating diluted earnings per share prior to the distribution of employee dividends at the next annual shareholders' meeting, the dilutive effect of these potential ordinary shares should also be considered.

(24) Cash flow information

A. Investment activities involving only partial cash payments:

| | Six Months Ended June 30 | |
|--|--------------------------|-----------|
| | 2025 | 2024 |
| Increase in property, plant and equipment | \$ 92,929 | \$ 43,405 |
| Increase in prepayment for equipment | 7,609 | 38,540 |
| Changes in payables for construction and equipment | 5,731 | 11,561 |
| Payments for acquisition of property, plant and equipment (Including prepayment for equipment) | \$ 106,269 | \$ 93,506 |

B. Significant Non-Cash Transactions

The Group's investments and financing activities in non-cash transactions from January 1 to June 30, 2024 were as follows:

- (a) On May 31, 2024, the Company acquired the remaining 52.67% equity of Bioflag International Corporation by issuing common stocks with a fair value totaling \$1,171,346 thousand (see Note 6(17)).

C. Changes in Debt from Fundraising Activities

| | Six Months Ended June 30, 2025 | | | |
|--|--------------------------------|--------------------|------------------|-------------------|
| | Short-term loans | Long-term loans | Bonds payable | Lease payables |
| January 1 | 1,262,000 | 1,061,121 | 4,189,621 | 17,387 |
| Cash flows from financing activities | (562,000) | (415,519) | — | (4,738) |
| New Lease | — | — | — | 709 |
| Other non-cash changes | — | — | 73,517 | — |
| June 30 | 700,000 | 645,602 | 4,263,138 | 13,358 |

| | Six Months Ended June 30, 2024 | | | |
|--|--------------------------------|--------------------|------------------|-------------------|
| | Short-term loans | Long-term loans | Bonds payable | Lease payables |
| January 1 | 330,000 | 913,982 | 4,350,826 | 26,569 |
| Cash flows from financing activities | 45,000 | 644,596 | — | (4,572) |
| New Lease | — | — | — | — |
| Other non-cash changes | — | — | 10,571 | — |
| June 30 | 375,000 | 1,558,578 | 4,361,397 | 21,997 |

(25) Capital management

Based on the characteristics of the industries in which the Company is currently operating and the future development of the Company, as well as taking into account factors such as changes in the external environment, the Company plans its needs for working capital, research and development expenses, and dividend payments in future periods, with a view to safeguarding the Company's ability to continue as a going concern, giving back to its shareholders while attending to the interests of other stakeholders, and maintaining an optimal capital structure to enhance shareholder value over the long run.

In order to maintain or adjust its capital structure, the Company may adjust the amount of dividends paid to shareholders by issuing new shares, distributing cash to shareholders or repurchasing its shares.

The Company regularly reviews the asset-liability ratio to monitor its funds. The capital of the Company is represented by "total equity" listed in the balance sheet, which is calculated as the total assets minus total liabilities.

The Company's debt ratios are listed as follows:

| Items | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------------|---------------|-------------------|---------------|
| Total liabilities | \$ 6,872,684 | \$ 7,482,692 | \$ 8,285,777 |
| Total assets | \$ 23,673,776 | \$ 25,537,175 | \$ 27,049,569 |
| Debt ratio | 29% | 29% | 31% |

(26) Financial instruments

A. Information on Fair Value of Financial Instruments

Except as detailed in the table below, the carrying amounts of the Group's financial instruments not measured at fair value (including cash and cash equivalents, time deposits, notes receivable, accounts receivable, other receivables, long-term and short-term loans, refundable deposits, bills payable, accounts payable and other payables) approximate their fair values. For information on the fair value of financial instruments that are measured at fair value, please refer to Note 6.(26)(C).

| | | June 30, 2025 | | |
|-----------------------|-----------------|-------------------|---------|-----------|
| | | Fair Value | | |
| | Carrying Amount | Level 1 | Level 2 | Level 3 |
| Financial liabilities | | | | |
| Convertible bonds | 4,263,138 | — | — | 4,242,085 |
| | | | | |
| | | December 31, 2024 | | |
| | | Fair Value | | |
| | Carrying Amount | Level 1 | Level 2 | Level 3 |
| Financial liabilities | | | | |
| Convertible bonds | 4,189,621 | — | — | 4,141,273 |
| | | | | |
| | | June 30, 2024 | | |
| | | Fair Value | | |
| | Carrying Amount | Level 1 | Level 2 | Level 3 |
| Financial liabilities | | | | |
| Convertible bonds | 4,361,397 | — | — | 4,286,726 |

B. Fair Value Hierarchy

The following table provides a related analysis of financial instruments that are measured at fair value after initial recognition and are categorized into Levels 1 through 3 based on the degree to which the fair value is observable. Each fair value level is defined as follows.

- (a) Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.
- (b) Level 2: Other than quoted prices included within Level 1, inputs are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- (c) Level 3: Derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

- C. Financial instruments measured at fair value are classified according to the nature, characteristics and risks of assets and liabilities and the level of the fair value hierarchy as follows:

| June 30, 2025 | | | | |
|---|--------------|------------|--------------|---------------|
| | Level 1 | Level 2 | Level 3 | Total |
| Financial assets at fair value through profit or loss - current: | | | | |
| Foreign listed stocks | \$ 304,961 | \$ — | \$ — | \$ 304,961 |
| Financial assets at fair value through profit or loss - non-current: | | | | |
| Foreign funds | \$ — | \$ — | \$ 4,342,700 | \$ 4,342,700 |
| Domestic unlisted stocks and emerging stocks | — | 171,141 | 14,277 | 185,418 |
| Foreign unlisted stocks and equity | — | — | 3,948,782 | 3,948,782 |
| Domestic listed stocks | 2,229,552 | — | — | 2,229,552 |
| Foreign listed stocks | 2,176,318 | — | — | 2,176,318 |
| Redemption rights | — | — | 1,355 | 1,355 |
| Total | \$ 4,405,870 | \$ 171,141 | \$ 8,307,114 | \$ 12,884,125 |
| Financial liabilities at fair value through profit or loss – non-current: | | | | |
| Put options | \$ — | \$ — | \$ 59,690 | \$ 59,690 |

| December 31, 2024 | | | | |
|---|--------------|------------|--------------|---------------|
| | Level 1 | Level 2 | Level 3 | Total |
| Financial assets at fair value through profit or loss - current: | | | | |
| Foreign listed stocks | \$ 257,998 | \$ — | \$ — | \$ 257,998 |
| Financial assets at fair value through profit or loss - non-current: | | | | |
| Foreign funds | \$ — | \$ — | \$ 4,434,912 | \$ 4,434,912 |
| Domestic unlisted stocks and emerging stocks | — | 174,156 | 18,511 | 192,667 |
| Foreign unlisted stocks and equity | — | — | 4,499,462 | 4,499,462 |
| Domestic listed stocks | 2,567,288 | — | — | 2,567,288 |
| Foreign listed stocks | 1,351,278 | — | — | 1,351,278 |
| Redemption rights | — | — | 3,117 | 3,117 |
| Total | \$ 3,918,566 | \$ 174,156 | \$ 8,956,002 | \$ 13,048,724 |
| Financial liabilities at fair value through profit or loss – non-current: | | | | |
| Put options | \$ — | \$ — | \$ 46,158 | \$ 46,158 |

| June 30, 2024 | | | | |
|---|--------------|------------|--------------|---------------|
| | Level 1 | Level 2 | Level 3 | Total |
| Financial assets at fair value through profit or loss - current: | | | | |
| Foreign listed stocks | \$ 302,637 | \$ — | \$ — | \$ 302,637 |
| Financial assets at fair value through profit or loss - non-current: | | | | |
| Foreign funds | \$ — | \$ — | \$ 4,427,444 | \$ 4,427,444 |
| Domestic unlisted stocks and emerging stocks | — | 185,438 | 11,877 | 197,315 |
| Foreign unlisted stocks and equity | — | — | 3,474,309 | 3,474,309 |
| Domestic listed stocks | 3,263,963 | — | — | 3,263,963 |
| Foreign listed stocks | 1,595,857 | — | — | 1,595,857 |
| Redemption rights | — | — | 8,990 | 8,990 |
| Total | \$ 4,859,820 | \$ 185,438 | \$ 7,922,620 | \$ 12,967,878 |
| Financial liabilities at fair value through profit or loss – non-current: | | | | |
| Put options | \$ — | \$ — | \$ 22,861 | \$ 22,861 |

D. The methods and assumptions used by the Group to measure fair value are explained as follows:

- (a) Where the Company adopts the market quotation as the fair value input (i.e., Level 1), it is listed as follows according to the characteristics of the instrument:

| Quoted price | market | Listed Stocks | Open-end Funds |
|--------------|--------|---------------|----------------|
| | | Closing price | Net worth |

- (b) Except for the above financial instruments with active markets, the fair values of other financial instruments are obtained by using valuation techniques or by reference to counterparty quotes. Fair values obtained using valuation techniques can be determined by reference to the current fair value of other instruments with substantially the same conditions and characteristics and discounted cash flow analysis or using other valuation techniques, including using models based on market information available at the consolidated balance sheet date (e.g., reference yield curve on Taipei Exchange and commercial paper rates on Reuters).

- (c) The evaluation of derivative financial instruments is based on widely accepted valuation models in the market, such as the discounted cash flow method and option pricing models. Forward foreign exchange contracts are usually evaluated based on the current forward exchange rate. Structured interest rate derivative financial instruments are evaluated using appropriate option pricing models, such as the Black-Scholes model, or other valuation methods, such as Monte Carlo simulation.
- (d) Quantitative information on significant unobservable inputs used in valuation models for Level 3 fair value measurements and sensitivity analysis of changes in significant unobservable inputs are provided as follows:

| | Fair value as of June 30, 2025 | Valuation technique | Significant Unobservable Inputs | Relationship between Inputs and Fair Value |
|--|-----------------------------------|-------------------------------|--|---|
| Non-derivative instruments: | | | | |
| Non-listed stocks | 3,528,493 | Comparable company approach | Price-to-earnings ratio, price-to-book ratio, enterprise value-to-operating income ratio, enterprise value-to-earnings before interest, taxes, depreciation, and amortization ratio, discount for lack of marketability, and control premium | The higher the ratios and control premium, the higher the fair value; The higher the discount for lack of marketability, the lower the fair value; |
| | - | Discounted cash flow approach | Long-term revenue growth rate, weighted average cost of capital, discount for lack of marketability, and discount for minority interest | The higher the weighted average cost of capital and discount for lack of marketability, the lower the fair value; The higher the long-term revenue growth rate and long-term net operating profit before tax, the higher the fair value. |
| Shares of venture capital company | 434,566 | Net asset value approach | Not applicable. | Not applicable. |
| Privately offered fund investments | 4,342,700 | Net asset value approach | Not applicable. | Not applicable. |
| Hybrid instrument: Put option | 59,690 | Monte Carlo simulation | Volatility and discount rate | The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value |
| Hybrid instrument: Right of redemption | 1,355 | Monte Carlo simulation | Volatility and discount rate | The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value |

| | Fair value as of June 30, 2024 | Valuation technique | Significant Unobservable Inputs | Relationship between Inputs and Fair Value |
|--|-----------------------------------|-------------------------------|--|---|
| Non-derivative instruments: | | | | |
| Non-listed stocks | 3,013,767 | Comparable company approach | Price-to-earnings ratio, price-to-book ratio, enterprise value-to-operating income ratio, enterprise value-to-earnings before interest, taxes, depreciation, and amortization ratio, discount for lack of marketability, and control premium | The higher the ratios and control premium, the higher the fair value; The higher the discount for lack of marketability, the lower the fair value; |
| | — | Discounted cash flow approach | Long-term revenue growth rate, weighted average cost of capital, discount for lack of marketability, and discount for minority interest | The higher the weighted average cost of capital and discount for lack of marketability, the lower the fair value; The higher the long-term revenue growth rate and long-term net operating profit before tax, the higher the fair value. |
| Shares of venture capital company | 472,419 | Net asset value approach | Not applicable. | Not applicable. |
| Privately offered fund investments | 4,427,444 | Net asset value approach | Not applicable. | Not applicable. |
| Hybrid instrument: Put option | 22,861 | Monte Carlo simulation | Volatility and discount rate | The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value |
| Hybrid instrument: Right of redemption | 8,990 | Monte Carlo simulation | Volatility and discount rate | The higher the volatility, the higher the fair value; the higher the discount rate, the lower the fair value |

E. Financial Risk Management Objectives

The Company's financial risk management objective is to manage market risk, credit risk, and liquidity risk associated with our operations. To mitigate these financial risks, we are dedicated to identifying, assessing, and mitigating market uncertainties in order to minimize the potential negative impact of market fluctuations on our financial performance.

The Board of Directors reviews the significant financial activities of in accordance with applicable regulations and internal control systems. The Company must adhere to the relevant financial operational procedures for overall financial risk management and division of responsibilities during the execution of financial plans.

F. Market Risk

Market risk refers to the potential impact of market price fluctuations, including exchange rates, interest rates, and equity security prices, on a company's earnings and the value of its financial instruments. The goal of market risk management is to maintain market risk at an acceptable level while maximizing investment returns.

(a) Exchange Rate Risk

Information on financial assets and liabilities denominated in foreign currencies that are material to the Group is listed as follows:

| | June 30, 2025 | | | December 31, 2024 | | | June 30, 2024 | | |
|---|------------------|---------------|-----------|-------------------|---------------|-----------|------------------|---------------|-----------|
| | Foreign currency | Exchange rate | NTD | Foreign currency | Exchange rate | NTD | Foreign currency | Exchange rate | NTD |
| (Foreign currency: Functional currency) | | | | | | | | | |
| <u>Financial assets</u> | | | | | | | | | |
| <u>Monetary items</u> | | | | | | | | | |
| USD: NTD | 5,406 | 29.30 | 158,156 | 37,465 | 32.785 | 1,228,300 | 37,164 | 32.45 | 1,205,970 |
| RMB: NTD | 14,772 | 4.091 | 60,431 | 10,260 | 4.478 | 45,944 | 13,819 | 4.445 | 61,426 |
| HKD: NTD | 8,771 | 3.732 | 32,735 | 89 | 4.222 | 373 | 214,096 | 4.155 | 889,570 |
| JPY: NTD | 13,423 | 0.203 | 2,730 | 106,128 | 0.210 | 22,276 | — | — | — |
| <u>Non-monetary items</u> | | | | | | | | | |
| USD: NTD | 156,701 | 29.30 | 4,591,351 | 150,938 | 32.785 | 4,948,505 | 157,125 | 32.45 | 5,098,841 |
| RMB: NTD | 1,084,263 | 4.091 | 4,435,719 | 1,072,623 | 4.478 | 4,803,206 | 752,600 | 4.445 | 3,345,305 |
| KRW: NTD | 646,258 | 0.0219 | 14,515 | 646,258 | 0.0225 | 14,515 | 1,111,800 | 0.0237 | 26,439 |
| HKD: NTD | 682,429 | 3.732 | 2,546,825 | 402,843 | 4.222 | 1,700,803 | 575,982 | 4.155 | 2,342,851 |
| CHF: NTD | 10,414 | 36.665 | 381,829 | 12,076 | 36.265 | 437,926 | 13,284 | 36.055 | 478,943 |

Due to a wide variety of foreign currencies involved in foreign currency transactions, exchange gains and losses are summarized and disclosed based on various foreign currencies of the consolidated company with material impact. All the exchange gains (losses) (including realized and unrealized) recognized for second quarter of 2025 and 2024 due to changes in exchange rates were NT\$(67,707) thousand and NT\$74,442 thousand, respectively.

(b) Interest Rate Risk

Interest rate risk refers to a type of risk in which the fair value of financial instruments changes due to market changes. The Company's interest rate risk mainly arises from floating-rate borrowings.

The carrying amounts of the Company's financial assets and liabilities that are exposed to interest rate risk at the balance sheet date are listed as follows:

| Item | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|---|---------------|-------------------|---------------|
| Exposed to cash flow interest rate risk | | | |
| — Financial liabilities | \$ 1,345,602 | \$ 2,323,121 | \$ 1,933,578 |

Sensitivity Analysis

The sensitivity analysis below is based on the interest rate risk of financial instruments as of the balance sheet date.

Floating-rate liabilities are analyzed based on the assumption that the amount of liabilities outstanding at the balance sheet date

remains outstanding throughout the year.

Assuming all other variables remain constant, a one percentage point increase in the interest rate would lead to a decrease in the Company's pre-tax net profit for second quarter of 2025 and 2024 by NT\$6,728 thousand and NT\$9,668 thousand, respectively.

G. Credit Risk

The Company faces potential credit risks primarily from its cash and cash equivalents, as well as financial instruments receivable. The Company holds its cash in various financial institutions and manages its exposure to credit risks at each institution. It believes that its cash and cash equivalents do not have a significant concentration of credit risks. The Company's main business is the sale of Western pharmaceuticals, serving a wide customer base across diverse sales regions. There is no significant concentration of credit risks in accounts receivable from transactions with individual customers.

H. Liquidity Risk

The objective of the Company's management of liquidity risk is to maintain sufficient cash and cash equivalents, highly liquid marketable securities and adequate bank facilities required for its operations, so that the Company possesses ample financial flexibility.

The table below summarizes the maturity profile of the Company's financial liabilities based on contractual undiscounted payments.

| June 30, 2025 | | | | |
|---------------------------|------------------|--------------|-------------------|--------------|
| Items | Less than 1 year | 1 to 5 years | More than 5 years | Total |
| Short-term loans | \$ 700,000 | \$ — | \$ — | \$ 700,000 |
| Accounts payable | 140,174 | — | — | 140,174 |
| Other payables and others | 781,737 | — | — | 781,737 |
| Lease liabilities | 9,763 | 3,923 | — | 13,686 |
| Bonds payable | 3,933,000 | 636,200 | — | 4,569,200 |
| Long-term loans | 36,723 | 608,879 | — | 645,602 |
| Total | \$ 5,601,397 | \$ 1,249,002 | \$ — | \$ 6,850,399 |

| December 31, 2024 | | | | |
|---------------------------|------------------|--------------|-------------------|--------------|
| Items | Less than 1 year | 1 to 5 years | More than 5 years | Total |
| Short-term loans | \$ 1,262,000 | \$ — | \$ — | \$ 1,262,000 |
| Accounts payable | 134,790 | — | — | 134,790 |
| Other payables and others | 433,292 | — | — | 433,292 |
| Lease liabilities | 9,395 | 8,145 | — | 17,540 |
| Bonds payable | 1,988,700 | 2,580,500 | — | 4,569,200 |
| Long-term loans | 641,123 | 416,945 | 3,053 | 1,061,121 |
| Total | \$ 4,469,300 | \$ 3,005,590 | \$ 3,053 | \$ 7,477,943 |

| June 30, 2024 | | | | |
|---------------------------|------------------|--------------|-------------------|--------------|
| Items | Less than 1 year | 1 to 5 years | More than 5 years | Total |
| Short-term loans | \$ 375,000 | \$ — | \$ — | \$ 375,000 |
| Accounts payable | 130,089 | — | — | 130,089 |
| Other payables and others | 1,497,629 | — | — | 1,497,629 |
| Lease liabilities | 9,499 | 12,806 | — | 22,305 |
| Bonds payable | — | 4,864,000 | — | 4,864,000 |
| Long-term loans | 234,854 | 1,314,811 | 8,913 | 1,558,578 |
| Total | \$ 2,247,071 | \$ 6,191,617 | \$ 8,913 | \$ 8,447,601 |

7. **RELATED PARTY TRANSACTIONS**

(1) Name and Relationship of Related Parties

| Name of Related Party | Relationship with the Group |
|---|--|
| Mycenax Biotech Inc. | Associate |
| BioEngine Technology Development Inc. | Subsidiary |
| Lumosa Therapeutics Co., Ltd. | Associate |
| BioGend Therapeutics Co., Ltd. | Associate |
| Anya Biopharm Inc. | Associate |
| TOT BIOPHARM Company Limited | Subsidiary of the Company's associate |
| Youluck International Inc. | Substantive related party |
| Ausnutria Dairy (Taiwan) Nutrition & Health Corporation | Substantive related party |
| Wechen Co., Ltd. | Directors of the Company |
| Youde Investment Consulting Co., Ltd. | The chairman of the Company is the person in charge of this Company. |

(2) Significant transactions between the Company and related parties are listed as follows:

A. Other expenses

| Type/Name of Related Party | Three Months Ended June 30 | | Six Months Ended June 30 | |
|-------------------------------|----------------------------|---------------|--------------------------|---------------|
| | 2025 | 2024 | 2025 | 2024 |
| Associate | \$ 849 | \$ 90 | \$ 999 | \$ 345 |
| Other related party | — | 24 | — | 24 |
| Total | <u>\$ 849</u> | <u>\$ 114</u> | <u>\$ 999</u> | <u>\$ 369</u> |

B. Lease income

| Type/Name of Related Party | Three Months Ended June 30 | | Six Months Ended June 30 | |
|---|----------------------------|-----------------|--------------------------|-----------------|
| | 2025 | 2024 | 2025 | 2024 |
| Other related party | \$ 238 | \$ 238 | \$ 475 | \$ 515 |
| Associate Lumosa Therapeutics Co., Ltd. | 1,834 | 1,747 | 3,655 | 3,495 |
| | 1,080 | 1,080 | 2,160 | 2,160 |
| Total | <u>\$ 3,152</u> | <u>\$ 3,065</u> | <u>\$ 6,290</u> | <u>\$ 6,170</u> |

C. Miscellaneous income

| Type/Name of Related Party | Three Months Ended June 30 | | Six Months Ended June 30 | |
|-------------------------------|----------------------------|-----------------|--------------------------|-----------------|
| | 2025 | 2024 | 2025 | 2024 |
| Associate | \$ 1,172 | \$ 1,154 | \$ 2,290 | \$ 2,551 |
| Other related party | 102 | 577 | 203 | 1,155 |
| Total | <u>\$ 1,274</u> | <u>\$ 1,731</u> | <u>\$ 2,493</u> | <u>\$ 3,706</u> |

D. Accounts receivable (payable)

The debts and claims of the Company and its subsidiaries with related parties are listed as follows:

(a) Other receivables

| Type/Name of Related Party | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------------------------|-----------------|----------------------|-----------------|
| Associate | \$ 1,020 | \$ 1,231 | \$ 990 |
| Other related party | 276 | 275 | 276 |
| Total | <u>\$ 1,296</u> | <u>\$ 1,506</u> | <u>\$ 1,266</u> |

(b) Other payables

| Type/Name of Related Party | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------------------------|---------------|----------------------|---------------|
| Associate | \$ 182 | \$ 32 | \$ 31 |

(c) Other current liabilities

| Type/Name of Related Party | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|-------------------------------|-----------------|----------------------|-----------------|
| Associate | \$ 1,019 | \$ 958 | \$ 989 |
| Other related party | 96 | 73 | 96 |
| Total | <u>\$ 1,115</u> | <u>\$ 1,031</u> | <u>\$ 1,085</u> |

(d) Guarantee deposits

| Type/Name of Related Party | June 30, 2025 | December 31, 2024 | June 30, 2024 |
|--------------------------------------|---------------|----------------------|---------------|
| BioGend Therapeutics Co., Ltd. | \$ 565 | \$ 565 | \$ 565 |

E. Information on Compensation of Key Management Personnel

| Items | Three Months Ended June 30 | | Six Months Ended June 30 | |
|--|----------------------------|----------|--------------------------|----------|
| | 2025 | 2024 | 2025 | 2024 |
| Salaries and other short- term employee benefits | \$ 3,685 | \$ 3,652 | \$ 7,338 | \$ 7,038 |
| Post- employment benefits | 27 | 27 | 54 | 81 |
| Share-based payments | 202 | — | 400 | — |
| Total | \$ 3,914 | \$ 3,679 | \$ 7,792 | \$ 7,119 |

8. PLEDGED ASSETS

The following assets of the Company have been provided to financial institutions as collateral for borrowings or have been placed under restrictions as to use:

| Name of Pledged Asset | June 30, 2025 | December 31, 2024 | June 30, 2024 | Contents of the Guaranteed Debt |
|---|---------------|----------------------|---------------|--|
| Property, plant and equipment | \$ 831,268 | \$ 827,283 | \$ 795,041 | Bank loan and credit line guarantee |
| Investment property, net | 660,229 | 662,247 | 664,276 | Bank loan and credit line guarantee |
| Investments accounted for using the equity method | 3,130,073 | 3,328,965 | 3,308,770 | Guarantee for bank loan |
| Financial assets at fair value through profit or loss | 72,450 | 75,600 | 252,000 | Initial public offering lockup |
| Financial assets at fair value through profit or loss | 2,145,671 | 1,565,165 | 1,436,098 | Guarantee for bank loan |
| Other financial assets - Time deposits | 924,990 | 924,974 | 920,430 | Corporate bond Guarantee and Bank Loan Collateral |
| Other financial assets - Restricted demand deposits | 257,378 | 258,509 | 305,949 | Guarantee Limits for Repayment Accounts and Corporate Bonds |
| Total | \$ 8,022,059 | \$ 7,642,743 | \$ 7,682,564 | |

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNIZED CONTRACT COMMITMENTS

- (1) As of June 30, 2025 and 2024, the consolidated companies had outstanding contracts for commissioned drug trial development amounting to NT\$9,884 thousand and NT\$4,357 thousand, of which NT\$5,139 thousand and NT\$3,068 thousand, respectively, had been paid in accordance with the contracts.
- (2) As of June 30, 2025 and 2024, the consolidated companies had outstanding capital expenditures for plant construction and equipment purchases amounting to NT\$88,714 thousand and NT\$62,549 thousand, respectively.
- (3) In August 2010, the Company commissioned TTY Biopharm Company Limited. to carry out formulation design and process development for R-PLGA long-acting freeze-dried powder injection dosage forms, with a commissioned development contract totaling \$20,000 thousand. As of June 30, 2025, the Company had paid \$12,500 thousand in accordance with the contract.
- (4) In October 2010, the Company entered into licensing contracts with the Industrial Technology Research Institute for the “D-PLGA Microparticle New Dosage Form Technology” and the “PLGA Microparticle Long-Acting Controlled-Release Platform Technology and Patent,” with a contract royalty of NT\$5,600 thousand payable and an annual royalty of 4% of the net sales of the products for 10 years from the date when sales of the products commences. As of June 30, 2025, the Company has paid a royalty of NT\$3,800 thousand.

10. SIGNIFICANT DISASTER LOSS: NONE

11. SIGNIFICANT SUBSEQUENT EVENTS: NONE

12. OTHERS: NONE

13. ADDITIONAL DISCLOSURES

- (1) Information on Significant Transactions and Investees

| No. | Items | Description |
|-----|--|-------------|
| 1. | Parties providing financing to others | None |
| 2. | Endorsement/guarantee provided | None |
| 3. | Significant securities held at the end of the period (excluding investments in subsidiaries, affiliated enterprises, and jointly controlled entities). | Table 1 |
| 4. | Purchases from and sales to related parties amounting to at least NT\$100 million or 20% of the paid-in capital | None |
| 5. | Receivables from related parties amounting to at least NT\$100 million or 20% of the paid-in capital | None |

(2) Disclosure of Information on Investees

| No. | Items | Description |
|-----|--|-------------|
| 1. | Information on investees (excluding information on investment in Mainland China) | Table 2 |
| 2. | Disclosure of control over investment companies | Table 1, 2 |

(3) Information on Investment in Mainland China:

| No. | Items | Description |
|-----|---|-------------|
| 1. | The name of the mainland investee company, main business items, paid-in capital, investment method, capital access situation, shareholding ratio, investment gains, and losses, the book value of the investment at the end of the period, repatriated investment gains and losses, and investment limits in mainland China | Table 3 |
| 2. | Significant transactions with investees in Mainland China, either directly or indirectly through a third area, as well as prices, payment terms, and unrealized gains or losses involved therein | None |

(4) Business relationships between the parent and subsidiaries and significant transactions between them: Table 4

14. **SEGMENT INFORMATION**

(1) Reportable Segment Information

The reportable segments provided to the main business decision-makers for the purposes of allocating resources and assessing segment performance are listed as follows:

Pharmaceutical division: Manufacturing and sales of various western pharmaceuticals.

Biotechnology venture capital- Investing in domestic and foreign biotechnology undertakings.

Glac segment - Manufacture and sale of probiotic products.

Other segments - Other businesses and operating segments that are not reported.

(2) The financial information of related reportable segments is analyzed as follows:

| | Second Quarter of 2025 | | | | | Mergers |
|--|-------------------------|-------------------------|--------------|----------------|----------------------------|------------|
| | Pharmaceutical Division | Biotech Venture Capital | Glac Segment | Other Segments | Adjustments and Write-offs | |
| Income from customers other than the parent and subsidiaries | 475,489 | — | 282,081 | — | — | 757,570 |
| Income from the parent company and consolidated subsidiary | — | 9,178 | — | — | (9,178) | — |
| Total revenue | 475,489 | 9,178 | 282,081 | — | (9,178) | 757,570 |
| Segment profit (loss) | 122,913 | 65,087 | (22,568) | (426) | | 165,006 |
| Investment income (loss) | | | | | | (275,735) |
| Ordinary income (expenses) | | | | | | 8,653 |
| Finance costs | | | | | | (114,615) |
| Net income before tax of continuing operations | | | | | | (216,691) |
| Identifiable assets | 595,036 | 15,828,342 | 1,605,293 | 10,283 | | 18,038,954 |
| Long-term equity investments | | | | | | 5,236,463 |
| Ordinary assets | | | | | | 398,359 |
| Total assets | | | | | | 23,673,776 |

| | Second Quarter of 2024 | | | | | |
|---|----------------------------|-------------------------------|-----------------|-------------------|-----------------------------------|------------|
| | Pharmaceutical Division | Biotech Venture Capital | Glac Segment | Other Segments | Adjustments and Write- offs | Mergers |
| Income from customers other than the parent and subsidiaries | 488,285 | — | 288,544 | — | — | 776,829 |
| Income from the parent company and consolidated subsidiary | — | 10,152 | 426 | — | (10,578) | — |
| Total revenue | 488,285 | 10,152 | 288,970 | — | (10,578) | 776,829 |
| Segment profit (loss) | 150,097 | (566,401) | 4,770 | (335) | | (411,869) |
| Investment income (loss) | | | | | | (177,885) |
| Ordinary income (expenses) | | | | | | (4,191) |
| Finance costs | | | | | | (114,315) |
| Net income before tax of continuing operations | | | | | | (708,260) |
| Identifiable assets | 608,003 | 18,552,101 | 1,611,039 | 11,364 | | 20,782,507 |
| Long-term equity investments | | | | | | 5,868,705 |
| Ordinary assets | | | | | | 398,357 |
| Total assets | | | | | | 27,049,569 |

Table 1

Significant marketable securities held by the Company as of June 30, 2025 (excluding investments in subsidiaries, associates, and joint ventures):

In Thousands of New Taiwan Dollars

| Name of Company Held | Type and Name of Securities | Relationship with Securities Issuer | Financial Statement Account | Ending Balance | | | |
|---------------------------|---|-------------------------------------|---|----------------|-----------------|--------------------|------------|
| | | | | Shares | Carrying Amount | Shareholding ratio | Fair Value |
| Center Laboratories, Inc. | Windtree Therapeutics, Inc. Ordinary shares | — | Financial assets at fair value through profit or loss - current | 27 | — | 11.10% | — |
| Center Laboratories, Inc. | Ausnutria Dairy Corporation Ltd. | — | Financial assets at fair value through profit or loss - current | 29,282,627 | 224,030 | 1.64% | 224,030 |
| Center Laboratories, Inc. | Hydrogenic Energy Fund I L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 124,475 | 19.39% | 124,475 |
| Center Laboratories, Inc. | Vivo Capital Fund X, L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 135,449 | 2.08% | 135,449 |
| Center Laboratories, Inc. | Vivo Capital Fund IX, L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 812,117 | 1.75% | 812,117 |
| Center Laboratories, Inc. | GL China Opportunities Fund III L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 697,386 | 4.17% | 697,386 |
| Center Laboratories, Inc. | Vivo Innovation Fund II, L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 313,024 | 5.06% | 313,024 |
| Center Laboratories, Inc. | Chengwei GP Participation Fund, L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 518,013 | 20.60% | 518,013 |
| Center Laboratories, Inc. | Vaxon Investment Inc. | — | Financial assets at fair value through profit or loss - non-current | 1,500 | 53,596 | 15.00% | 53,596 |
| Center Laboratories, Inc. | Helicase Venture Fund I, L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 40,765 | 30.00% | 40,765 |
| Center Laboratories, Inc. | Fangyuan PCJ Fund II L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 160,423 | 19.80% | 160,423 |
| Center Laboratories, Inc. | GL China Opportunities Fund IV L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 1,036,568 | 16.39% | 1,036,568 |
| Center Laboratories, Inc. | Efficient Biomedical Corp. | — | Financial assets at fair value through profit or loss - non-current | 160,000 | 12,074 | 16.00% | 12,074 |
| Center Laboratories, Inc. | T-E Pharma Holding (Cayman) Preferred stock | — | Financial assets at fair value through profit or loss - non-current | 18,750,000 | 85,068 | 6.37% | 85,068 |
| Center Laboratories, Inc. | Onward Therapeutics SA Preferred stock | — | Financial assets at fair value through profit or loss - non-current | 11,316,700 | 381,829 | 17.75% | 381,829 |
| Center Laboratories, Inc. | TransPacific Medtech Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 3,129 | 28,996 | 31.29% | 28,996 |
| Center Laboratories, Inc. | T-E Meds Holding (Cayman) | — | Financial assets at fair value through profit or loss - non-current | 2,500,000 | 29,978 | 1.17% | 29,978 |

| Name of Company Held | Type and Name of Securities | Relationship with Securities Issuer | Financial Statement Account | Ending Balance | | | |
|--------------------------------------|--|-------------------------------------|---|----------------|-----------------|--------------------|------------|
| | | | | Shares | Carrying Amount | Shareholding ratio | Fair Value |
| Center Laboratories, Inc. | AmMax, BIO, INC. | — | Financial assets at fair value through profit or loss - non-current | 602,200 | 8,298 | 1.59% | 8,298 |
| Center Laboratories, Inc. | AiViva_Series A Preferred Share | — | Financial assets at fair value through profit or loss - non-current | 4,031,052 | 22,938 | 16.54% | 22,938 |
| Center Laboratories, Inc. | Shine-On Biomedical Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 2,829,813 | 160,557 | 5.68% | 160,557 |
| Center Laboratories, Inc. | iXensor Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 1,864,066 | 10,584 | 6.08% | 10,584 |
| Center Laboratories, Inc. | Taiwan Depository & Clearing Corporation | — | Financial assets at fair value through profit or loss - non-current | 12,500 | 2,203 | — | 2,203 |
| Center Laboratories, Inc. | Ausnutria Dairy Corporation Ltd. | — | Financial assets at fair value through profit or loss - non-current | 117,635,644 | 899,983 | 6.61% | 899,983 |
| Center Laboratories, Inc. | Ever Supreme Bio Technology Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 10,420,880 | 1,620,447 | 11.90% | 1,620,447 |
| Center Laboratories, Inc. | Ever Fortune. Ai Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 3,978,000 | 274,482 | 4.18% | 274,482 |
| Center Laboratories, Inc. | Adimmune Corporation | — | Financial assets at fair value through profit or loss - non-current | 5,845,000 | 97,027 | 1.36% | 97,027 |
| Centerlab Investment Holding Limited | Shuimu Development Limited | — | Financial assets at fair value through profit or loss - non-current | — | 15,505 | 33.00% | 15,505 |
| Centerlab Investment Holding Limited | HebeCell Holding Limited - Preferred stock | — | Financial assets at fair value through profit or loss - non-current | 31,710 | — | 1.14% | — |
| Centerlab Investment Holding Limited | GL JKP Holding L.P. | — | Financial assets at fair value through profit or loss - non-current | — | 351,975 | 8.00% | 351,975 |
| Centerlab Investment Holding Limited | Nanjing Chengwei Shiji Equity Investment Partnership (Limited Partnership) | — | Financial assets at fair value through profit or loss - non-current | — | 488,976 | 10.00% | 488,976 |
| Centerlab Investment Holding Limited | UAC Technology (Jiaxing) Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | — | 160,546 | 16.20% | 160,546 |
| Centerlab Investment Holding Limited | Bioflag Nutrition Corporation (KY) | — | Financial assets at fair value through profit or loss - non-current | 5,038,672 | 158,941 | 10.26% | 158,941 |
| Center Laboratories Limited (HK) | Shanghai Bao Pharmaceutical Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 7,981,066 | 2,208,221 | 14.59% | 2,208,221 |
| Center Biotherapeutics, Inc. | Scindy Pharmaceutical (Suzhou) | — | Financial assets at fair value through profit or loss - non-current | — | 12,584 | 15.79% | 12,584 |
| Center Biotherapeutics, Inc. | GenEditBio Limited (Cayman) | — | Financial assets at fair value through profit or loss - non-current | 4,322,881 | 65,546 | 2.86% | 65,546 |

| Name of Company Held | Type and Name of Securities | Relationship with Securities Issuer | Financial Statement Account | Ending Balance | | | |
|---------------------------------------|--|-------------------------------------|---|----------------|-----------------|--------------------|------------|
| | | | | Shares | Carrying Amount | Shareholding ratio | Fair Value |
| Center Venture Holding I Limited (HK) | Jacobi o(CAY)Pharmaceuticals Co., Ltd. | — | Financial assets at fair value through profit or loss - current | 635,300 | 10,290 | 0.08% | 10,290 |
| Center Venture Holding I Limited (HK) | Jacobi o(CAY)Pharmaceuticals Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | 78,801,300 | 1,276,335 | 9.95% | 1,276,335 |
| Center Venture Holding II Limited | Guangzhou Hybot Technology Co., Ltd. | — | Financial assets at fair value through profit or loss - non-current | — | 380,268 | 8.33% | 380,268 |
| BioEngine Technology Development Inc. | Jacobio (CAY)Pharmaceuticals Co., Ltd. | — | Financial assets at fair value through profit or loss - current | 4,361,400 | 70,641 | 0.55% | 70,641 |
| BioEngine Technology Development Inc. | Adimmune Corporation | — | Financial assets at fair value through profit or loss - non-current | 14,313,000 | 237,596 | 3.33% | 237,596 |

Table 2

Information on investees:(excluding information on investments in mainland china)

In Thousands of New Taiwan Dollars, Except for Shares

| Investor Company | Investee Company | Address | Main Business | Original Investment Amount | | Balance as of June 30, 2025 | | | Net Income (Loss) of the Investee | Share of Profit (Loss) of Investee | Note |
|---------------------------|--|--|---|----------------------------|-------------------|-----------------------------|------------|-----------------|-----------------------------------|------------------------------------|--|
| | | | | June 30, 2025 | December 31, 2024 | Shares | Percentage | Carrying Amount | | | |
| Center Laboratories, Inc. | Fangyuan Growth SPC PCJ Healthcare Fund SP | Sertus Chambers, Governors Square, Suite # 5-204, 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY1-1104, Cayman Islands | Investment | 211,653 | 280,021 | — | 33.33% | 287,329 | 92,447 | 30,813 | — |
| Center Laboratories, Inc. | PCJ Capital Management Limited | Sertus Chambers, Governors Square, Suite # 5-204, 23 Lime Tree Bay Avenue, P.O. Box 2547, Grand Cayman, KY1-1104, Cayman Islands | Management consultant | — | — | — | 25% | — | — | — | — |
| Center Laboratories, Inc. | Center Biotherapeutics Inc. | Sea Meadow House, Blackburne Highway, PO Box 116, Road Town, Tortola, British Virgin Islannds | Investment | 66,152 | 66,152 | 2,228,283 | 100.00% | 91,062 | (28,801) | (28,801) | Subsidiary |
| Center Laboratories, Inc. | BioEngine Technology Development Inc. | 7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Investment management consultant | 428,777 | 428,777 | 98,437,500 | 100.00% | 609,521 | (35,901) | (10,178) | Subsidiary |
| Center Laboratories, Inc. | Mycenax Biotech Inc. | 7F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County, Taiwan (R.O.C.), Hsinchu Science Park | Manufacturing and sales of biopharmaceuticals | 1,003,282 | 1,003,282 | 41,974,314 | 20.27% | 366,310 | (266,299) | (53,983) | The Company's legal representative is the chairman of this Company |
| Center Laboratories, Inc. | TOT BIOPHARM International Company Limited | 15/F MAY MAY BUILDING, 683-685 NATHAN ROAD KOWLOON, HONG KONG | Investment | 2,433,620 | 2,433,620 | 213,311,700 | 27.60% | 2,781,558 | 17,898 | (2,828) | — |
| Center Laboratories, Inc. | Centerlab Investment Holding Limited (HK) | FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong | Investment | 525,885 | 1,194,127 | 17,103,584 | 100.00% | 1,191,468 | (61,515) | (61,515) | Subsidiary |
| Center Laboratories, Inc. | Center Laboratories Limited (HK) | FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong | Investment | 1,188,313 | 1,188,313 | 39,871,908 | 100.00% | 2,208,206 | (237,485) | (237,485) | Subsidiary |
| Center Laboratories, Inc. | Lumosa Therapeutics Co., Ltd. | 4F-1, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Drug development | 1,856,191 | 1,841,579 | 57,863,874 | 34.35% | 556,700 | (252,102) | (86,338) | — |
| Center Laboratories, Inc. | Medeon Biodesign, Inc. | 5F., No. 116, Hougang St., Shilin Dist., Taipei City, Taiwan (R.O.C.) | Medical device development | 737,017 | 770,495 | 26,220,028 | 28.42% | 313,756 | (356,153) | (105,920) | — |
| Center Laboratories, Inc. | BioGend Therapeutics Co., Ltd. | 4F, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Development of orthopedic medical devices | 512,676 | 512,676 | 37,580,008 | 30.24% | 264,168 | (56,478) | (18,227) | — |

| Investor Company | Investee Company | Address | Main Business | Original Investment Amount | | Balance as of June 30, 2025 | | | Net Income (Loss) of the Investee | Share of Profit (Loss) of Investee | Note |
|---|--|--|--|----------------------------|-------------------|-----------------------------|------------|-----------------|-----------------------------------|------------------------------------|----------------|
| | | | | June 30, 2025 | December 31, 2024 | Shares | Percentage | Carrying Amount | | | |
| Center Laboratories, Inc. | A2 + Healthcare Venture Fund L.P. | 6F., No. 135, Sec. 3, Minsheng E. Rd., Songshan Dist., Taipei City, Taiwan (R.O.C.) | Venture capital | 250,000 | 250,000 | — | 49.50% | 262,817 | (10,501) | (5,198) | — |
| Center Laboratories, Inc. | Anya Biopharm Inc. | 6F., No. 378, Changchun Rd., Zhongshan Dist., Taipei City, Taiwan (R.O.C.) | Drug development | 16,277 | 16,277 | 8,276,369 | 16.86% | 78,939 | (68,305) | (14,177) | — |
| Center Laboratories, Inc. | Center Venture Holding I Limited | FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong | Investment | 1,913,443 | 1,913,443 | 1 | 100% | 1,286,648 | 860,688 | 860,688 | Subsidiary |
| Center Laboratories, Inc. | Center Venture Holding II Limited | FLAT/RM 1204, Yu Sung Boon Bldg., 107-111 Des Voeux Road, Central, Hong Kong | Investment | 451,032 | 451,032 | 13,929,351 | 100% | 380,296 | (105,362) | (105,362) | Subsidiary |
| Center Laboratories, Inc. | Center Venture Holding III Limited | Level 2, Lotemau Centre Building, Vaea Street, Apia, Samoa | Investment | — | — | 1 | 100% | — | — | — | Subsidiary |
| Center Laboratories, Inc. | Cytoengine Co., Ltd. | 4F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Drug development | 50,000 | 50,000 | 5,000,000 | 40% | 12,556 | (8,198) | (3,279) | — |
| Center Laboratories, Inc. | KriSan Biotech Co., Ltd. | 5F., No. 28, Ln. 31, Sec. 1, Huan dong Rd., Xinshi Dist., Tainan City, Taiwan (R.O.C.) | Western pharmaceutical manufacturing industry | 201,500 | 201,500 | 10,075,000 | 17.53% | 163,103 | (47,718) | (10,868) | — |
| Center Laboratories, Inc. | Bioflag International Corporation | 4 th Floor, Harbour Place, 103 South church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands | Investment | 2,210,039 | 1,388,476 | 66,654,539 | 100% | 1,428,326 | (6,077) | (29,830) | Subsidiary |
| Centerlab Investment Holding Limited (HK) | ASEAN Bio & Medical Platform Investment L.P. | 25F, City Air Tower, 159-9, Samsung-dong, Gangnam-gu, Seoul, Korea | Investment | 53,945 | 53,945 | — | 30.00% | 14,515 | — | — | — |
| Bioflag International Corporation | Bioflag Co., Ltd. | Sea Meadow House, Blackburne Highway, Road Town, British Virgin Islands | Investment | — | 1,836,445 | — | — | — | 4,509 | 4,509 | Sub-subsidiary |
| Bioflag International Corporation | Glac Biotech Co., Ltd. | 4F-2, No. 17, Guoji Rd., Xinshi Dist., Tainan City, Taiwan (R.O.C.) | Manufacturing and sales of functional probiotics | 1,092,386 | — | 72,171,000 | 100.00% | 1,692,098 | (3,477) | (7,991) | Sub-subsidiary |
| Bioflag Co., Ltd. | Glac Biotech Co., Ltd. | 4F-2, No. 17, Guoji Rd., Xinshi Dist., Tainan City, Taiwan (R.O.C.) | Manufacturing and sales of functional probiotics | — | 1,704,696 | — | 100.00% | — | (3,477) | 4,514 | Sub-subsidiary |
| Glac Biotech Co., Ltd. | OmniPro Biotech Co., Ltd. | No.10, Xinsheng St., Minxiong Township, Chiayi County, Taiwan (R.O.C.) | General food manufacturing | 15,000 | 15,000 | 1,500,000 | 100.00% | 2,282 | 41 | 41 | Sub-subsidiary |
| Glac Biotech Co., Ltd. | Ezadd Co., Ltd. | 7F., No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Functional probiotics sales | 1,990 | 1,990 | 199,000 | 99.50% | 1,235 | 1 | 1 | Sub-subsidiary |
| BioEngine Technology Development Inc. | Lumosa Therapeutics Co., Ltd. | 4F-1, No. 3-2, Park St., Nangang Dist., Taipei City, Taiwan (R.O.C.) | Drug development | 31,683 | 31,683 | 1,053,218 | 0.62% | 19,549 | (252,102) | (1,573) | — |

| Investor Company | Investee Company | Address | Main Business | Original Investment Amount | | Balance as of June 30, 2025 | | | Net Income (Loss) of the Investee | Share of Profit (Loss) of Investee | Note |
|---------------------------------------|--|--|---|----------------------------|-------------------|-----------------------------|------------|-----------------|-----------------------------------|------------------------------------|----------------|
| | | | | June 30, 2025 | December 31, 2024 | Shares | Percentage | Carrying Amount | | | |
| BioEngine Technology Development Inc. | TOT BIOPHARM International Company Limited | 15/F MAY MAY BUILDING, 683-685 NATHAN ROAD KOWLOON, HONG KONG | Investment | 84,468 | 84,468 | 7,646,300 | 0.99% | 101,945 | 17,898 | (101) | — |
| BioEngine Technology Development Inc. | BioEngine Development I Limited | FLAT/RM 1204, YU SUNG BOON BLDG., 107-111 DES VOEUX ROAD CENTRAL, HONG KONG | Investment | 22,890 | 22,890 | 1,000,000 | 100.00% | 18,815 | (426) | (426) | Sub-subsidiary |
| BioEngine Technology Development Inc. | A2+ Biotech Consulting Co., Ltd. | 6F., No. 135, Sec. 3, Minsheng E. Rd., Songshan Dist., Taipei City, Taiwan (R.O.C.) | Management consultant | 4,000 | 4,000 | 400,000 | 33.33% | 5,240 | 2,870 | 957 | — |
| BioEngine Technology Development Inc. | Anya Biopharm Inc. | 6F., No. 378, Changchun Rd., Zhongshan Dist., Taipei City, Taiwan (R.O.C.) | Drug development | 68,400 | 68,400 | 2,340,000 | 4.77% | 22,254 | (68,305) | (4,008) | — |
| BioEngine Technology Development Inc. | Mycenax Biotech Inc. | 7F., No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County, Taiwan (R.O.C.), Hsinchu Science Park | Manufacturing and sales of biopharmaceuticals | 32,370 | 32,370 | 780,000 | 0.38% | 6,652 | (266,299) | (1,003) | — |

Table 3

Information on Investment in Mainland China:

In Thousands of New Taiwan Dollars

| Investee Company | Main Businesses | Paid-in Capital | Method of Investment (Note 1) | Accumulated Outflow of Investment from Taiwan as of January 1, 2025 | Investment Flows | | Accumulated Outflow of Investment from Taiwan as of June 30, 2025 | Net Income (Loss) of the Investee Company | Percentage of Ownership | Share of Profits (Losses) (Note 2) | Carrying Amount as of June 30, 2025 | Accumulated Inward Remittance of Earnings as of June 30, 2025 |
|---|---|--------------------------|--|---|------------------|--------|---|---|-------------------------|------------------------------------|-------------------------------------|---|
| | | | | | Outflow | Inflow | | | | | | |
| TOT BIOPHARM Co., Ltd. | Production, research and development of anti-cancer capsules and liposome injection | USD NT\$222,450 thousand | (2) TOT BIOPHARM International Company Limited (Hong Kong) | 698,807 | — | — | 698,807 | 29,588 | 27.60% | 8,166 | 833,122 | — |
| Jiang Su Tung Yang Biopharm Tech Co., Ltd. | Sales, research and development of western medicine | USD NT\$2,000 thousand | (2) TOT BIOPHARM International Company Limited (Hong Kong) | 13,684 | — | — | 13,684 | (102) | 27.60% | (28) | 7,554 | — |
| Dongyuan Biotech (Shanghai) Co., Ltd. | Pharmaceutical research and development | USD NT\$3,730 thousand | (2) TOT BIOPHARM International Company Limited (Hong Kong) | 24,956 | — | — | 24,956 | (195) | 27.60% | (54) | 3,958 | — |
| Shanghai Bao Pharmaceutical Co., Ltd. | Company specializing in the development of recombinant proteins and antibody drugs | RMB NT\$46,860 thousand | (2) Center Laboratories Limited(HK) | 1,188,191 | — | — | 1,188,191 | — | 14.59% | — | 2,208,221 | — |
| Beijing Jinkangpu Food Science & Technology Co., Ltd. | Sub-packaging and production of food additives and compound food additives | RMB NT\$10,000 thousand | (2) Centerlab Investment Holding Limited | 198,471 | — | — | 198,471 | — | 5.00% | — | 316,778 | — |

| Investee Company | Main Businesses | Paid-in Capital | Method of Investment (Note 1) | Accumulated Outflow of Investment from Taiwan as of January 1, 2025 | Investment Flows | | Accumulated Outflow of Investment from Taiwan as of June 30, 2025 | Net Income (Loss) of the Investee Company | Percentage of Ownership | Share of Profits (Losses) (Note 2) | Carrying Amount as of June 30, 2025 | Accumulated Inward Remittance of Earnings as of June 30, 2025 |
|--|---|--------------------------|--|---|------------------|--------|---|---|-------------------------|------------------------------------|-------------------------------------|---|
| | | | | | Outflow | Inflow | | | | | | |
| Beijing Kangpuni Detection Technology Co., Ltd. | Technology of Detection | RMB NT\$1,000 thousand | (2)Centerlab Investment Holding Limited | 22,053 | — | — | 22,053 | — | 5.00% | — | 35,197 | — |
| Scindy Pharmaceutical (Suzhou) | Medical Research and Experimental Development | RMB NT\$15,833 thousand | (2)Center Biotherapeutics Inc. | 66,120 | — | — | 66,120 | — | 15.79% | — | 12,584 | — |
| Nanjing Chengwei Shiji Equity Investment Partnership (Limited Partnership) | Venture capital | RMB NT\$660,000 thousand | (2)Centerlab Investment Holding Limited | 391,214 | 98,538 | — | 489,752 | — | 10.00% | — | 488,976 | — |
| UAC Technology (Jiaxing) Co., Ltd. | Manufacture and Design of Specialized Equipment | EUR NT\$23,045 thousand | (2)Centerlab Investment Holding Limited | 174,143 | — | — | 174,143 | — | 16.20% | — | 160,546 | — |
| Bioflag Co., Ltd. | Biological health product research and development and related technical consultation | RMB NT\$109,218 thousand | (2)Centerlab Investment Holding Limited Transfer of Investment to Bioflag | — | — | — | — | — | 10.26% | — | 158,941 | — |
| Bioflag (Anhui) Co., Ltd. | Research and development, production, and sales of probiotics and other microorganisms and related products | RMB NT\$36,242 thousand | (2)Centerlab Investment Holding Limited Transfer of Investment to Bioflag | — | — | — | — | — | 10.26% | — | | — |
| Beijing Shundu Pharmaceutical Research Institute Co., Ltd. | Pharmaceutical technology development and consulting | RMB NT\$6,123 thousand | (2)BioEngine Development I Limited | — | — | — | — | (423) | 100% | (423) | 10,228 | — |
| Guangzhou Hybot Technology Co., Ltd. | Sales of new energy vehicles | RMB NT\$300,000 thousand | (2)Center Venture Holding II Limited | 451,000 | — | — | 451,000 | — | 8.33% | — | 380,268 | — |

| Company name | Accumulated Investment in Mainland China as of June 30, 2025 | Investment Amounts Authorized by Investment Commission, MOEA | Upper Limit on the Company's Investments in Mainland China |
|---------------------------|--|---|--|
| | | | Net worth* 60% |
| Center Laboratories, Inc. | NT\$2,907,273 thousand | USD 80,373 thousand RMB 664,475 thousand EUR 5,500 thousand | 10,080,652 |

Note 1: Method of investment can be divided into three types as follows:

- (1) Direct investment in Mainland China.
- (2) Investment in Mainland China through a company in a third area (Please indicate the invested company in a third area).
- (3) Other methods.

Note 2: The recognition of investment gains and losses for the current period is based on unaudited financial statements.

Table 4

Parent-Subsidiary Company Business Relation and Important Transactions - For the six months ended June 30, 2025

In Thousands of New Taiwan Dollars

| No. (Note 1) | Name of Company | Name of Counterparty | Nature of Relationship (Note 2) | Intercompany Transactions | | | | |
|-----------------|---------------------------|---------------------------------------|------------------------------------|--|--|--------|--|--|
| | | | | Financial Statement Account | | Amount | Transaction Terms | Percentage of Consolidated Net Revenue or Total Assets (Note 3) |
| 0 | Center Laboratories, Inc. | Glac Biotech Co., Ltd. | 1 | Other receivables | Other payables | 705 | Based on contracts signed between both parties | — |
| | | Glac Biotech Co., Ltd. | 1 | Guarantee deposits | Refundable deposits | 1,834 | Based on contracts signed between both parties | 0.01% |
| | | Glac Biotech Co., Ltd. | 1 | Lease income/Investment loss | Depreciation/Interest expenses | 5,959 | Based on contracts signed between both parties | 0.79% |
| | | Glac Biotech Co., Ltd. | 1 | Other receivables/Long-term investment | Lease liabilities | 4,543 | Based on contracts signed between both parties | 0.02% |
| | | | | | Right-of-use assets/ Lease liabilities | 84,994 | Based on contracts signed between both parties | 0.36% |
| | | Glac Biotech Co., Ltd. | 1 | Lease income | Rental expenses | 468 | Based on contracts signed between both parties | 0.06% |
| | | Glac Biotech Co., Ltd. | 1 | Other income | Other expenses | 2,508 | Based on contracts signed between both parties | 0.33% |
| | | BioEngine Technology Development Inc. | 1 | Other income | Entrusted management fee | 649 | Based on contracts signed between both parties | 0.09% |
| | | BioEngine Technology Development Inc. | 1 | Other receivables | Other payables | 673 | Based on contracts signed between both parties | — |
| | Glac Biotech Co., Ltd. | OmniPro Biotech Co., Ltd. | 1 | Accounts receivable | Accounts payable | 750 | Based on contracts signed between both parties | — |

Note 1: The business transaction information between the parent company and its subsidiaries should be indicated in the serial number column, respectively. The method of filling in the serial number is as follows:

- (1) For the parent, please indicate “0” in the code column.
- (2) For investees, please indicate “1” in the code column and arrange the investees by company type.

Note 2: There are five types of relationship with the trader. Just indicate the type:

- (1) The parent to the subsidiary.
- (2) Subsidiary to the parent.
- (3) Between subsidiaries.

Note 3: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets. If it is an asset-liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, the cumulative amount in the period accounts for the total consolidated total. It is calculated by the method of receipt.

Table 4

Parent-Subsidiary Company Business Relation and Important Transactions - For the six months ended June 30, 2024

In Thousands of New Taiwan Dollars

| No. (Note 1) | Name of Company | Name of Counterparty | Nature of Relationship (Note 2) | Intercompany Transactions | | | | |
|-----------------|-----------------------------------|---------------------------------------|---------------------------------------|---|---|---------|--|--|
| | | | | Financial Statement Account | | Amount | Transaction Terms | Percentage of Consolidated Net Revenue or Total Assets (Note 3) |
| 0 | Center Laboratories, Inc. | Glac Biotech Co., Ltd. | 1 | Other receivables | Other payables | 1,109 | Based on contracts signed between both parties | — |
| | | Glac Biotech Co., Ltd. | 1 | Advance receipts | Prepaid expenses | 623 | Based on contracts signed between both parties | — |
| | | Glac Biotech Co., Ltd. | 1 | Guarantee deposits | Refundable deposits | 1,105 | Based on contracts signed between both parties | — |
| | | Glac Biotech Co., Ltd. | 1 | Lease income/ Investment loss | Depreciation/Interest expenses | 3,626 | Based on contracts signed between both parties | 0.47% |
| | | Glac Biotech Co., Ltd. | 1 | Lease Income | Rental expenses | 490 | Based on contracts signed between both parties | 0.06% |
| | | Glac Biotech Co., Ltd. | 1 | Other income | Other expenses | 2,087 | Based on contracts signed between both parties | 0.27% |
| | | Glac Biotech Co., Ltd. | 1 | Other receivables/ Long-term investment | Lease liabilities/ Right-of-use assets | 2,777 | Based on contracts signed between both parties | 0.01% |
| | | BioEngine Technology Development Inc. | 1 | Other income | Entrusted management fee | 307 | Based on contracts signed between both parties | 0.04% |
| | | Bioflag International Corporation | 1 | Financial assets at amortized cost – non-current | Bonds payable | 200,000 | Based on contracts signed between both parties | 0.74% |
| | | Bioflag International Corporation | 1 | Other receivables | Other payables | 13,775 | Based on contracts signed between both parties | 0.05% |
| | | Bioflag International Corporation | 1 | Interest income | Interest expenses | 4,000 | Based on contracts signed between both parties | 0.51% |
| | | Center Biotherapeutics Inc. | 1 | Interest expenses | Interest income | 59 | Based on contracts signed between both parties | 0.01% |
| | Bioflag International Corporation | Bioflag Co., Ltd. | 1 | Other receivables | Other payables | 270,504 | Based on contracts signed between both parties | 1.00% |
| | | Bioflag Co., Ltd. | 1 | Interest income | Interest expenses | 254 | Based on contracts signed between both parties | 0.03% |
| | Genlac Biotech Inc. | Bioflag Co., Ltd. | 2 | Other receivables | Other payables | 164,186 | Based on contracts signed between both parties | 0.61% |
| | Glac Biotech Co., Ltd. | OmniPro Biotech Co., Ltd. | 1 | Accounts receivable | Accounts payable | 2,007 | Based on contracts signed between both parties | 0.01% |
| | | OmniPro Biotech Co., Ltd. | 1 | Sales revenue | Cost of goods sold | 426 | Based on contracts signed between both parties | 0.05% |
| | | OmniPro Biotech Co., Ltd. | 1 | Commission expenses | Other income | 28 | Based on contracts signed between both parties | — |
| | OmniPro Biotech Co., Ltd. | Glac Biotech Co., Ltd. | 2 | Accounts receivable | Accounts payable | 30 | Based on contracts signed between both parties | — |

- Note 1: The business transaction information between the parent company and its subsidiaries should be indicated in the serial number column, respectively. The method of filling in the serial number is as follows:
- (1) For the parent, please indicate “0” in the code column.
 - (2) For investees, please indicate “1” in the code column and arrange the investees by company type.
- Note 2: There are five types of relationship with the trader. Just indicate the type:
- (1) The parent to the subsidiary.
 - (2) Subsidiary to the parent.
 - (3) Between subsidiaries.
- Note 3: The calculation of the ratio of the transaction amount to the consolidated total revenue or total assets. If it is an asset-liability account, it is calculated as the ending balance of the consolidated total assets; if it is a profit and loss account, the cumulative amount in the period accounts for the total consolidated total. It is calculated by the method of receipt.